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CHAPTER 1 
General introduction 
1.1. Clinical studies with daunorubicin 
Since the introduction of daunorubicin (DNR) as an antitumor agent into clinical 
studies in the late 1960s, its use and study of its activity have been confined almost 
exclusively to the acute leukemias. In fact, there have been no systematic studies of 
the efficacy of DNR in patients with solid tumors of various types (1-3), despite the 
fact that the drug is closely related to doxorubicin (DOX), an anticancer drug with a 
broad clinical spectrum (4). The possibility that DNR might be at least as active as 
DOX in solid tumors remains to be determined (5,6). 
With respect to the acute leukemias, it has been shown that both children and adults 
with acute lymphocytic leukemia (ALL) show significant clinical responses to 
chemotherapy programs that include DNR (7,8). In addition, DNR is effective in the 
treatment of pediatric acute myeloid leukemia (AML) (9,10). DNR was introduced 
into clinical trials in adult AML at a time when treatment of this type of leukemia 
was beginning to receive greater attention as a potential target for specific therapy 
(11,12). Until that time AML had a very poor prognosis. Untreated AML was rapidly 
fatal with a median survival of 2-6 months. Death frequently resulted from infection 
or haemorrhage, caused by the granulocytopenia and thrombocytopenia that was the 
consequence of the bone marrow suppression resulting from the infiltration of the 
bone marrow by leukemic cells. In those days hematologists questioned whether 
patients with AML should be treated at all (13), since most of the available cytotoxic 
drugs were relatively ineffective in patients with AML and only showed significant 
activity in the treatment of ALL. In AML these drugs (e.g., methotrexate, vincristine, 
prednisone, 6-mercaptopurine, cyclophosphamide, L-asparaginase and cytosine 
arabinoside) resulted in complete remission (CR) rates of less than 25%. It then 
appeared that DNR as a single agent produced CR rates of 20-50% (14-17). When 
DNR was subsequently combined with cytosine arabinoside (ara-C) during remission 
induction (RI) therapy, survival of all treated AML patients was significantly better 
than when DNR was used as a single agent. Studies were then performed that 
identified the combination regimen of DNR and ara-C (e.g., DNR on days 1 through 3 
associated with a seven-day treatment of ara-C) with slight variations as probably 
being the most efficacious RI regimen used to date (18-20). Since then, complete 
remissions in 60-80% of patients with AML have been reported repeatedly (19-22). 
Despite the advances in the treatment of AML, CR rates and their durations vary 
significantly among patients and the biological basis of this is only partly 
understood (23). Patients who do not enter remission are a heterogeneous group 
including individuals with persistent leukemia due to inadequate reduction of drug 
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sensitive leukemic cells or the early reappearance of leukemic cells following initial 
marrow hypoplasia after chemotherapy. In these cases, the leukemia appears 
resistant to the drugs used. Other individuals die from infections or hemorrhagic 
complications during marrow hypoplasia during or after RI therapy. Outcome of RI 
therapy is determined by a multiplicity of interactive factors (listed in Table 1). 
Understanding of these factors and their role in the response to therapy is essential 
for further progress of therapy of AML. 
Table 1: 
Factors which determine the outcome of remission induction therapy in AML 
Patients characteristics {pretreatment) 
I. age: 
2. past medical history of prior cytotoxic 
therapy, preleukemic syndrome or the 
presence of specific chromosomal 
aberrations: 
3. medical complications (e.g., infection, 
bleeding, organ failure), concomitant 
Qisease and the use of other drugs: 
AML, cell properties 
4. sensitivity to chemotherapeutic agents: 
5. maturation stage of leukemic stem cell: 
Pharmacological factors 
6. chemotherapeutic agents used and ability 
of patient to metabolize and excrete 
these drugs: 
7. access to pharmacologically sanctuary 
sites and ability of uptake of drugs by 
AML cells: 
determines tolerance to side effects of 
chemotherapy 
determines bone marrow repopulating 
capacity after chemotherapy or prognosis 
determine early death from intercurrent 
disease 
determines response to therapy 
determines repopulation and 
differentiation capacity of AML 
determine toxicity of regimen 
determine delivery of chemotherapeutic 
agents to target tissue in vivo 
Apart from the above mentioned factors, there are many other clinical, hematological, 
cytological, and cytochemical parameters that are of prognostic value in predicting the 
likelihood of achieving CR. Favourable factors may include: a) female sex, b) the presence 
of Auer rods (24), c) more differentiated FAB classification subtypes (M2, M3, M4, M5b) 
(25,26), and d) translocation (8;21) and inversion-16 patterns on the pretreatment 
cytogenetic analysis (27). Unfavourable factors may include: a) high tumor load (28, 29), 
b) decreased levels of serum albumin and calcium, and elevated levels of blood glucose, 
blood urea nitrogen, and serum creatinine (24), and c) the presence of MY4 and MY7 
myeloid surface antigens on the AML cells (30). 
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Besides optimization of supportive care to prevent death from intercurrent 
complications (e.g., transfusion policy, antibiotics, in vivo application of 
hematopoietic growth factors or other biological response modifiers), further 
improvements in CR rate may be expected from a) the development of more effective 
and b) less toxic agents, c) more effective/less toxic time scheduling of available 
agents in combination therapy or d) a more rational approach to treatment through 
individualization of therapy. Particularly, individual differences of drug handling 
may play an important role in determining the clinical response to therapy. 
The aim of the present study was to identify pharmacologic variables of DNR that 
may give insight into the mechanisms which are responsible for individual 
differences of clinical response of AML patients to RI therapy. The phases of these 
investigations are outlined in more detail in paragraph 1.3. As a background for 
those investigations the pharmacology of DNR will be introduced briefly (paragraph 
1.2.). 
1.2. 
1.2.1. 
Daunorubicin 
Physical-chemistry 
In 1959 the microorganism isolated from a soil sample collected in Apulia, Italia, 
was recognized as a new species and named Streptomyces peucetius (31). The first 
clinically effective compound was discovered independently in Italy and in France in 
1963. The group of DiMarco and coworkers performed its isolation from S. 
peucetius and designated the compound daunomycin (32). Dubost and co-workers 
gave the name rubidomycin to their product isolated from S. coeruleoribidus (33). 
When the identity of these two antibiotics was established, the name daunorubicin 
was chosen to reflect the dual origin (in France the name rubidomycin is still used). 
A different strain of S. peucetius, known as the caesius variety, produced the 
14-hydroxy analog of DNR, doxorubicin (34). 
DNR and DOX belong to the group of anthracycline antitumor antibiotics. The name 
anthracycline is based upon structural features of compounds in this family: they 
have anthraquinone chromophores related to those of the tetracyclines (35). Besides 
antitumor activity, DNR shows moderate inhibiting effects on some gram-positive 
and gram-negative bacteria, and fungi (36), and on bacteriophages and 
double-stranded DNA viruses (37,38). 
Fig.1 shows the chemical structures of DNR and DOX. The DNR molecule is 
constituted of a hydrophobic part, the aglycone (daunomycinone; red visible color), 
which is linked to the aminosugar by a glycoside band, involving the 7-hydroxyl 
group of the aglycone. The aminosugar (daunosamine) forms the hydrophilic part of 
the drug molecule (Fig.1). The intact aminosugar residue is essential for biological 
activity (39). DNR, as well as DOX, contain both acidic and basic functions, such as 
the amino group in the sugar moiety and the two phenolic groups in the aglycone 
part of the molecule which can donate a proton, whereas in concentrated acid one of 
the quinone carbonyl groups can accept a proton (40,41). Alterations in the chemical 
structure in either the aglycone part or the aminosugar part of the molecule 
influence its polarity and the charge, which both determine its affinity to cell 
structures like membranes and DNA (42). Most anthracyclines, having identical 
fluorophores, exhibit the same fluorescent properties. On excitation of the DNR 
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Fig. 1: 
Chemical structure of daunorubicin 
and doxorubicin 
R = H (daunorubicin) 
R = OH (doxorubicin) 
molecule at 470 nm in ethanol emission maxima could be detected at 554 and 585 
nm (43) (Fig.2). Fluorescence analysis of the anthracyclines can be used for 
bioanalytical purposes, such as the analysis in tissues and body fluids, and for 
pharmacokinetic studies. 
1.2.2. Mechanism of action 
Three potential mechanisms of action by which DNR kills tumor cells and causes its 
characteristic toxicities have been described: 
A. Interaction with DNA and RNA synthesis 
DNA has generally been assumed to be the primary target of the biological action of 
DNR. The binding of DNR to DNA involves more than one class of sites (44). On one 
hand DNR may intercalate with DNA and on the other hand it may bind weakly to 
DNA. As regards the 'strong' intercalation complex with DNA (45,46), the B and C 
rings of the chromophore of the molecule (Fig.l) intercalate between adjacent base 
pairs into the double helix of DNA (Fig.3) (47). Whether DNR preferentially binds to 
certain base compositions or base sequences is somewhat controversial (48). Some 
have suggested preference for G-C- (49,50) others for A-T-sequences (51). 
The 'weakly' bound DNR molecules are thought to be attached to DNA by means of 
electrostatic interaction involving the DNA phosphate groups and the DNR amino 
group (44). Upon binding of the drug to DNA the properties of the template DNA are 
modified, leading to inhibition of the processes of DNA replication and RNA 
transcription (52,53). Intercalation of DNR together with inhibition of topoisomerase 
II (54,55) leads to enhanced DNA fragmentation, DNA breaks and chromosomal 
aberrations with inhibition of repair. In addition, the mechanism of action of DNR 
involves the inhibition of DNA- and RNA-polymerases (56,57). Among the various 
species of RNA, synthesis of ribosomal RNA appears to be the most sensitive to DNR 
(58). 
B. Free radical formation 
DNR can be enzymatically reduced to semiquinone free radicals (catalysed by the 
microsomal P450 reductase) (59-61), which in turn can generate reactive oxygen 
radicals such as superoxide, hydrogen peroxide or hydroxyl radical (Fig.4). These 
reactive oxygen species may cause DNA strand scission (62-64) and peroxidation of 
lipids causing membrane damage of cells and of mitochondria (64). 
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Fig. 2: 
Fluorescence spectra of daunorubicin 
I = excitation spectrum 
2 = fluorescence spectrum 
700 
Cellular targets other than the nucleus may be of importance in the DNR action. This 
is suggested by the complex formation of anthracyclines with negatively charged 
phospholipids like cardiolipin (65-67). This phospholipid is a major component of the 
inner membranes of mitochondria which are abundant in the cardiac muscles. The 
binding of anthracyclines to cardiolipin together with the formation of toxic oxygen 
and hydroxyl radicals have been proposed as mechanisms for the cardiac toxicity 
(63,65,68). Furthermore, it appears that anthracyclines immobilized by a polymer 
linkage can be actively cytotoxic without entering the cell, merely by interaction at 
the plasma membrane (69,70). 
Other mechanisms of action of DNR have been proposed as well. These include 
bioreductive alkylation of DNA by anthracyclines (71-73), inhibition of the 
mitochodrial respiratory chain (74,75), and metal ion chelation (76). 
Fig. 3: 
Intercalation of 
daunorubicin into DNA 
DNA 
Daunorubicin- DNA 
complex 
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Fig. 4: 
Mechanism for enzymatic microsomal (NADPH cytochrome P-450 reductase) 
catalysis of daunorubicin free radical formation with subsequent 
nonenzymatic rearrangement to 7-deoxyaglycone product 
FPred = flavoprotein reduced 
FPox = flavoprotein oxidized 
S = the aminosugar daunosamine. 
NADP 
NADPH FPox 
0 OH 
H 
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1.2.3. Metabolism 
0 
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Following in vivo administration DNR is degraded by two processes occuring 
simultaneously (Fig. 5). 
A. Reduction of the side-chain carbonyl group to produce the main metabolite 
daunorubicinol (DOL) occurs via a ubiquitous, cytoplasmatic NADPH-requiring 
aldo-keto reductase (77), an enzyme which is native to all tissues. In blood aldo-keto 
reductase is present in erythrocytes and leukocytes, including leukemic blast cells 
(78), but not in platelets or plasma (79). The presence of the active enzyme in blood 
cells implicates that DNR metabolism can occur in blood samples after they are 
drawn (80). The metabolite DOL has high specific inhibitory activity on DNA and 
RNA synthesis once it is in the cells (81). DOL is more polar than the parent drug 
DNR, which limits its rate of uptake by the cells and thus the resulting intracellular 
concentration (42). However, since the antitumor effect of DOL approaches that of 
DNR, DOL can contribute to the antitumor and pharmacological activity of DNR in 
man. 
B. Reductive cleavage of the daunosamine sugar from DNR and DOL to form 
aglycones is mediated by microsomal, NADPH-dependent cytochrome P450 
reductase. This reaction is exquisitely sensitive to molecular oxygen and takes place 
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Fig. 5: 
Metabolism of daunorubic:in by I) carbonyl reduction to daunorubicinol and 
l) reductive glycoside cleavage to daunomycinone and daunosamine 
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especiallly in the liver (82). The aglycones appears to be biologically inactive (83), 
although it is possible that the aglycone products have biological activity when 
liberated intracellularly (84). 
Various other metabolites are detected in human urine and in bile (85), but their 
biological activities have not yet been reported. 
1.2.4. Side effects 
The use of DNR is limited by its toxicity to normal tissues. The major acute 
dose-limiting toxicities are bone marrow depression and stomatitis. Irreversible 
cardiomyopathy represents another important side effect that limits the cumulative 
dose used over time (86). The incidence of cardiomyopathy increases significantly 
above a cumulative dose of 450 mg/m2 and may attend in 2.2% of the patients that 
have received total dosages of DNR of more than 650 mg/m2 (87). 
Other side effects include nausea, vomiting and (reversible) alopecia (86). 
Anthracyclines also cause serious local tissue necrosis after extravasation due to 
long persistence of the drug in the skin (88,89). Finally, some drug interactions of the 
anthracyclines have been reported i.e., interactions with barbiturates (90), with 
heparin (91) and with amphotericin B (92). 
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1.2.5. Resistance 
The development of resistance to the anthracycline drugs represents one of the major 
obstacles to effective therapy with these agents. Preclinical studies aimed at the 
elucidation of mechanisms of anticancer drug resistance have shown that 
mammalian cell lines can develop so-called multiple drug resistance (MDR) after in 
vitro challenging. When these cell lines are continuously exposed to gradually 
increasing doses of naturally occuring anticancer agents, such as anthracycline 
antibiotics and vinca alkaloids, drug resistant sublines can be obtained which are 
not only resistant to the selecting agent, but also cross-resistant to a variety of 
structurally unrelated drugs (93,94). This MDR phenotype is characterized by: 
a) decreased drug accumulation (95) due to active drug efflux (96,97), 
b) increased intracellular drug accumulation and subsequent restoration of drug 
sensitivity by exposure to a variety of agents (such as calcium channel blockers 
and calmodulin antagonists) (98), and 
c) gene amplification (99) and overexpression of a 170-kDa transmembrane 
glycoprotein (P-glycoprotein) (100). 
It is generally accepted now that MDR is due to overexpression of P-glycoprotein, 
which functions in the plasma membrane as a rapid energy-dependent unidirectional 
drug efflux pump (101-104). In human two P-glycoprotein genes have been 
identified (mdr1 and mdr3) (104-106). Until now only human mdr1 gene has been 
shown to induce MDR (105). A number of agents, including calcium antagonists such 
as verapamil and calmodulin inhibitors such as cyclosporin-A, interfere with 
outward drug transport and thereby restore chemosensitivity (98,107-110). 
There is accumulating evidence that MDR can also occur in human hematological 
malignancies, including AML (111-116). Normal bone marrow cells, spleen cells and 
lymphocytes have a very low level of mdr1 expression. Both in untreated as well as 
in chemotherapy treated AML patients overexpression of the mdr1 gene can be 
detected. However, the overexpression of mdr1 occurs more frequently in leukemic 
cells from treated AML patients than in those from untreated AML patients 
(113,114,116). In addition, mdr1 overexpression in AML cells is associated with a 
decreased drug accumulation in vitro that can be restored by cyclosporin-A (116). 
This indicates that drug-resistant leukemia patients whose tumor cells show the 
MDR phenotype could theoretically benefit from treatment with cytotoxic drugs in 
combination with inhibitors of the P-glycoprotein drug pump. 
The data presented above appear to form a cohesive and logical explanation for the 
emergence of anthracycline resistance. However, other mechanisms for resistance are 
possible and probable (117). These include: 
a) alterations in drug binding, either to the cell membrane or to the nucleus: 
changes in drug efflux which occur following manupilation of cellular 
metabolism might result from an alteration in intracellular binding sites, possibly 
by phosphorylation and a change in configuration, thus causing a change in the 
'releasable' fraction of drug (118); 
b) differences in reduction to the semiquinone radicals: cells differ in their ability to 
reduce anthracyclines and it may be possible that anthracycline-resistant cells 
have defective reductase enzyme systems, whereby the drug is inadequately 
activated to form free radicals (119,120). 
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1.2.6. Pharmacokinetics and pharmacodynamics 
The area of clinical pharmacology that describes the concentration-time course of 
the drug, which is related to drug absorption, distribution, metabolism and 
excretion, is generally referred to as pharmacokinetics. On the basis of these data, 
parameters can be defined which describe the fate of the drug and its metabolites in 
the body (121,122). Pharmacodynamics is the discipline that deals with the 
relationship between the drug concentration and the specific biological effect (123), 
which in the case of AML can be considered as the relationship between DNR 
pharmacokinetics and killing of leukemic blast cells. 
A. Assays 
Drug concentration measurements represent the core of any pharmacokinetic study. 
Methods developed to determine anthracyclines in biological fluids are multifold and 
include the following: 
1. Total extractable plasma fluorescence (spectrophotofluorimetry) (43,124,125); thin 
layer chromatography (TLC) followed by elution and fluorescent measurement 
(126); 
2. TLC with quantitative fluorescence scanning of the thin-layer plate by 
radioimmunoassay (127); 
3. Isotopic methods (128). 
However, with the introduction of reliable extraction procedures and 
high-performance liquid chromatographic (HPLC) detection methods (129), sensitive 
and selective methods became available that appear of value for comparative 
pharmacokinetic studies in vitro (cell lines) and in vivo (animal/man). More recently, 
flow cytometric techniques have opened possibilities for further research with regard 
to anthracycline concentration measurements in individual cells (130-132). 
B. In vitro studies 
In vitro studies have shown that, at the cellular level, the anthracycline drug 
accumulates rapidly intracellularly and reaches a steady state concentration which 
exceeds the extracellular level by a factor of 450-800 (133,134). The cellular drug 
uptake is directly proportional to the extracellular drug concentration (42), increases 
at higher temperature (135) and at higher pH (136), and is inversely related to the 
number of incubated cells (137). Fluorescent microscopy (138) and subcellular 
fractionation studies (133) of cells have shown that the drug is highly concentrated 
in the nuclei and in the lysosomes. 
The final intracellular drug concentration is a complex function of: 
a) the passive (non-energy dependent) influx of drug involving a carrier-mediated 
transport across the cell membrane, 
b) intracellular drug transport and nuclear accumulation of DNR and binding to 
DNA, RNA and cellular proteins, as well as 
c) 
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active and/or passive drug efflux from the cytoplasm to the extracellular 
environment (139,140). 
C. In vivo studies: experimental animals 
The in vivo pharmacokinetics of DNR and DOX have been studied extensively in a 
variety of animal species (141-144). These studies demonstrated that the drugs are 
cleared from the plasma rapidly and that they are incorporated in tissues, in 
particular in kidneys, heart and lungs. The DNR and DOX concentrations in tissues 
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and the tissue-plasma ratios differ significantly in various organs. In addition, the 
drugs are extensively metabolized in most animals. However, in rats no metabolism 
of DOX could be demonstrated (145}. The drugs are slowly excreted into the bile 
(which is the primary route of excretion) and into the urine. 
Comparative pharmacokinetic studies of the anthracyclines in vivo in animal-tumor 
models is useful in order to obtain information which cannot be obtained in man. 
Studies with the brown Norway acute myeloid leukemia (BNML), a rat model which 
resembles AMLin humans (146), have provided information as regards: 
a) the distribution kinetics of leukemic cells in the body (147), 
b) comparative distribution kinetics of DOX (148) and DNR (149) between normal 
tissues and leukemia-infiltrated tissues in vivo and, 
c) pharmacokinetics of DNR in normal tissues and bone marrow toxicity (150,151). 
For instance, results of these studies have shown that in the presence of a high 
leukemic cell load the intravenously injected DNR is rapidly taken up and retained 
by the leukemic tumor mass in e.g., spleen, liver and lungs, and that, as a 
consequence, the bone marrow functions as a pharmacological sanctuary (149). 
However, it has also been shown, that after infusion of BNML cells in the rat about 
50% of leukemic cells lodge in the bone marrow (147). It is not known to what 
extent DNR carried by cells in vivo can add to the transport of DNR to target tissues 
inAML. 
D. In vivo studies: man 
Initial reports of DNR pharmacokinetics in man have been concerned with DNR 
given as intravenous (IV) bolus injections in patients with solid tumors or leukemia 
(152,153). Following IV administration of DNR, a rapid fall in plasma levels of the 
drug was observed, associated with substantial extravascular accumulation in most 
tissues, except those of the central nervous system (142). The disappearance of DNR 
from plasma follows first-order elimination of a biphasic nature, with a rapid initial 
(= distribution) phase followed by a long elimination phase (153). The rapid decline 
in plasma DNR levels is associated with a fast appearance of the main metabolite 
DOL in the plasma (153). The excretory pathway of DNR and DOL is primarily biliary 
(90%) with urinary excretion occuring to a lesser degree (10%) (154,155). Since the 
main excretory pathway for DNR is through the bile, it has been recommended that 
the dose be reduced in the presence of hepatic dysfunction (156). 
Extensive tissue determinations of anthracycline uptake in man have never been 
made, except for rare 'postmortem' examinations of DOX in cancer patients (157) 
and some cellular pharmacokinetic studies of DNR in AML patients (154,158-160). In 
AML patients it was shown, that after DNR administration the drug accumulated in 
the leukemic cells up to concentrations which exceeded the plasma concentrations 
400-4000 times, although with great interindividual differences among patients. 
Although the numbers of patients investigated in these studies were small, the 
combined results suggest that plasma concentrations of DNR provide little 
information on the drug concentrations in the leukemic cells and in the tissues. 
Until now, limited data have been reported on a relationship between plasma 
pharmacokinetic parameters of anthracyclines and clinical response. For instance, it 
has been demonstrated that high plasma levels of DOX are associated on one hand 
with death during RI therapy, and on the other hand in patients attaining remission, 
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long remissions (161). However, these results could not be confirmed for DNR 
(instead of DOX) plasma levels (162). In addition, high plasma levels of aglycones 
(which are inactivated metabolites of DNR) are associated with Rl failure mainly due 
to toxicity, while low levels are associated with a greater probability to attain CR. 
Plasma concentrations of the active compounds (DNR and DOL) were not associated 
with response (162). However, since DNR exerts its effect mainly intracellularly, 
measurements of leukemic cell content of DNR in AML patients during treatment 
with DNR, rather than plasma DNR concentrations, may be prognostic of clinical 
(i.e., therapeutical and/or toxicological) outcome. As yet, studies dealing with 
intracellular drug concentrations and clinical correlations have not been performed. 
I.J. Introduction to the experimental work 
Although progress has been made in pharmacokinetic areas, incomplete knowledge 
of the relationship between cytotoxic drug concentration-time profiles and drug 
effects has remained an obstacle for optimization of therapy. We assumed that 
estimation of drug concentrations in plasma and tissue may help to explain why 
individuals have different responses to treatment with the drug. Since the targets of 
the cytostatic therapy in AML patients, i.e., the circulating leukemic cells and the 
leukemic cells in the bone marrow are easily accessible, these patients offer a unique 
opportunity to study the pharmacokinetics in different pharmacological 
compartments. Therefore, it was our objective to simultaneously monitor the DNR 
concentrations attained in vivo in blood and bone marrow of patients with AML 
during the RI treatment. In an attempt to estimate the predictive value of cellular 
DNR concentrations in AML, we tried to elucidate possible relationships between the 
cellular pharmacokinetic parameters of DNR and: 
a) the plasma distribution kinetics of the drug, 
b) the tumor load of the patient and, 
c) the clinical response to treatment. 
In addition, a preclinical study was planned in the rat with the purpose of 
investigating certain aspects of cellular DNR pharmacokinetics in pharmacological 
compartments that are not accessible in man. 
In chapter 2 experimental determinants of the quantification of cellular DNR using 
HPLC were analysed: i.e., the quality of isolation and separation of nucleated cells 
from other cells and the recovery of DNR from these cells using a specific extraction 
method. The parameters that were established were applied in the subsequent 
clinical studies dealing with monitoring of the in vivo cellular and plasma 
pharmacokinetics of DNR in patients with AML. 
In chapter 3 laser flow cytometry was applied to measure DNR concentrations in 
individual cells and in isolated nuclei and the applicability of flow cytometry for 
measuring cellular DNR concentrations after in vivo uptake was evaluated. The data 
were compared with the results obtained with HPLC. 
In chapter 4 the in vivo distribution kinetics of DNR entrapped in cells (normal 
nucleated cells or leukemia cells) were determined in normal and leukemic rats, 
using a leukemia model which in many ways closely resembles AML in humans. 
These kinetics were then compared to the distribution kinetics of DNR after an IV 
injection of free DNR of the same dosage. The possible role of cells to transport DNR 
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to different pharmacological compartments (i.e., bone marrow, spleen, liver and 
heart) was investigated. 
In chapter 5 the in vivo cellular DNR concentrations in blood and bone marrow were 
determined in 37 patients with AML during first RI treatment and compared to the 
simultaneously observed plasma distribution kinetics of the drug. In addition, the 
data were correlated to the tumor load and the clinical response to treatment. 
In chapter 6 DNR concentrations in blood and bone marrow cells of 17 patients with 
AML were determined after in vivo uptake of the drug, and compared with the 
results obtained with HPLC. In addition, the usefulness of flow cytometry to 
determine the concentrations of DNR in subpopulations of hemopoietic cells, i.e., in 
particular in the leukemic blast cell fraction, was evaluated. 
The results of the investigations are discussed in Chapter 7. 
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CHAPTER2 
Quantitative evaluation of intracellular 
uptake of daunorubicin in acute 
myeloid leukemia: a method analysis 
Esther Kokenberg, Pieter Sonneveld, Kees Nooter, Koos van der Steuijt and Bob 
Lowenberg 
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Summary 
Critical technical parameters to establish a reliable method for quantifying the 
intracellular content of anthracyclines were evaluated in patients with acute myeloid 
leukemia (AML); two methods were used for the isolation of leukocytes from the 
peripheral blood and two methods, for the extraction of daunorubicin (DNR), 
daunorubicinol (DOL), and doxorubicin (DOX) from these cells, followed by drug 
analysis using high-performance liquid chromatography (HPLC). At 0-4 ·c the 
recovery of leukocytes after methylcellulose separation was low (64%). Cold 
hypotonic lysis gave better recovery (100%) when performed at the same 
temperature. After low-volume (2 ml extraction mixture) drug extraction from 
isolated leukocytes, the recoveries of DNR, DOL, and DOX from the cells were low, 
and they were inversely related to the cellularity of the sample, irrespective of the 
amount of drug in the cells. With high-volume extraction (5 ml extraction mixture) 
the recoveries were better (up to 95% ), but they remained dependent on the 
cellularity. A correction factor accounting for these cellularity-related recoveries 
was applied to calculate the DNR and DOL contents of the leukocytes. Finally, using 
this information, plasma and cellular DNR and DOL levels were measured in seven 
patients with AML during their first course of remission induction therapy. The 
cellular DNR levels appeared to vary over a broad range and did not correlate with 
plasma pharmacokinetics. 
Introduction 
Daunorubicin (DNR) is a major drug in the treatment of acute myeloid leukemia 
(AML). In current treatment protocols the drug is frequently administered during 
remission induction (RI), consolidation, and maintenance therapy. The clinical 
response of patients with AML treated with anthracycline-containing chemotherapy 
varies considerably. Although the complete remission rate of AMI.. is high (60-70%) 
(8), a significant proportion of cases is primarily refractory. In the responding 
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patients the relapse rate of AML is high, owing to incomplete eradication of leukemic 
cells. The duration of response may vary from 2 months to several years. The reasons 
for this considerable variation in therapeutic effect may relate to different biological 
properties of the leukemic cells per se and their susceptibility to the cytoreductive 
effect of the drug, or to interindividual differences in drug penetration into the 
leukemic cell. Monitoring of daunorubicin and doxorubicin (DOX) plasma levels in 
AML patients during RI has yielded little information to add to our understanding of 
the reasons for the interindividual variation in initial response and eventual relapse 
(13). Moreover, the plasma concentrations of DNR and its major metabolite 
daunorubicinol (DOL) were not correlated with the concentrations of the drug in 
leukemic cells obtained from AML patients (6,11). Since DNR apparently exerts its 
major effect by intercalation into DNA (1,7,19), the nucleus of leukemic cells can be 
regarded as the major target of DNR therapy. Determinations of DNR and its 
metabolite in leukemic cells, rather than in plasma, are likely to provide more 
important parameters for estimation of the response to the drug. However, little is 
known about the methodological factors of the assay, and therefore the results of the 
studies may suffer from inadequate technical performance or reproducibility. We 
report an analysis of certain factors which directly affect the outcome of the 
intracellular drug measurements. Different methods of sampling AML cells from the 
peripheral blood, followed by high-performance liquid chromatography for 
evaluation of the DNR content, were examined. The quality of isolation and 
separation of the leukemic blasts from other cells and the extraction method were 
investigated for maximal recovery and for avoidance of artefacts. The data obtained 
were then applied to a clinical study in seven newly diagnosed AML patients treated 
with daunorubicin as part of the remission induction chemotherapy regimen. 
Materials and methods 
Drugs and chemicals 
Daunorubicin, daunorubicinol and doxorubicin were a gift from Farmitalia Carlo 
Erba (Milan, Italy). The drugs were freshly dissolved in methanol and diluted in 
water to give a final concentration of 200 J.Lg/ml, and stored at -20 ·c in the dark. 
The HPLC solvents were HPLC grade reagents (J.T. Baker Chemicals B.V., Deventer, 
Holland). Dulbecco's phosphate-buffered saline (PBS) at pH 7.3 had the following 
composition in deionized water: NaCl136.8 mM, KC12.7 mM, Na2HP04 8.1 mM and 
KH2P04 1.5 mM. Lysis buffer (290 mosmol) had the following composition in 
deionized water: NH4Cl155.1 mM, NaHC03 11.9 mM and EDTA 0.1 mM. 
Methylcellulose (Dow Methocel, viscosity 4000 cps) was dissolved in deionized water 
and Dulbecco's medium to prepare a final2% solution (w/v}. 
Collection and isolation of human peripheral blood leukocytes 
Human leukocyte suspensions were prepared from huffy coats, which were obtained 
as a byproduct following single donor platelet pheresis (Aminco, Celtrifuge 1), with 
ACD-A as an anticoagulant. We wished to achieve maximal leukocyte recovery from 
the blood for measurement of drug uptake and compared two separation methods: 
A. Sedimentation of the cells in methylcellulose. One part of the blood was mixed 
with one part of ice-cold PBS and methylcellulose 40:1 (v/v} in a siliconized tube 
and placed on ice. After 20 min the leukocytes were harvested. The same 
procedure was repeated for the residual cells of the pellet. Immediately after 
collection, the cells were placed on ice. Then, the cells were washed with PBS at 
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4 ·c in order to remove the remaining methylcellulose (10 min, 450 g). Finally, 
the leukocytes were resuspended in PBS. 
B. Separation by hypotonic lysis. After washing the cell suspension with PBS to 
remove the plasma, the cells were resuspended in a small volume of PBS. One 
part of the cell suspension was :rrllxed with four parts of lysis buffer and placed 
on melting ice. After 10 min the suspension was centrifuged, the supernatant was 
removed, the leukocytes were washed with PBS to remove the remaining lysis 
buffer, and finally the leukocytes were resuspended in PBS. 
Then the cell suspension was diluted with PBS to final concentrations of 1, 3, 10 and 
30 x 109 cells/1. Total cell counts following separation were compared with the initial 
count of the blood sample before separation. DNR, DOL, and DOX (50 J.il of each) 
were added to 2 ml of each leukocyte suspension to give final concentrations of 0.1, 
0.5, and 2.0 p.g DNR, DOL and, DOX per ml suspension. After 5 min the samples were 
stored at -20 ·c until further processing. 
Collection and isolation of whole blood, plasma and leukocytes from AML patients 
The criteria of the French-American-British working party were used to diagnose 
AML (4). The patients were treated according to the EORTC LAM-6 protocol. 
Remission induction chemotherapy consisted in DNR 45 mg/m2 body surface on days 
1, 2 and 3 by IV bolus, cytosine arabinoside (ara-C) 200 mg/m2 IV on days 1-7 and 
vincristine 1 mg/m2 IV on day 2. 
Blood samples (10 ml) were drawn into tubes with EDTA as the anticoagulant, 
immediately before and at +5, +10, +20, +30 min and at +1, +4, +8, and +24 h, after 
the first dose of DNR was administered during the first course of RI treatment. The 
samples were cooled to 4 ·c, the cells were counted, and 2 ml whole blood was taken 
from each sample and frozen. Another part of each of these samples was centrifuged 
at 4 ·c, after which the plasma was collected and frozen. The huffy coat was 
depleted of erythrocytes by cold hypotonic lysis. The remaining leukocytes, usually 
myeloblasts, as determined by microscopic examination of stained cells, were 
resuspended in PBS, counted, and also frozen. 
Therapeutic end-points of remission induction regiments 
The criteria for evaluating response were those established by the Cancer and Acute 
Leukemia Group B (14). In brief, complete remission (CR) or partial remission (PR) is 
achieved when after one or two RI courses the proportion of leukemic cells has to 
< 5.0% (CR) or to 5.1%-25.0% (PR) while hematopoiesis and peripheral blood counts 
have returned to normal. 
Failures of the induction treatment were characterized according to Preisler (12): 
Type 1: absolute drug resistance; type 2: relative drug resistance; type 3: 
regeneration failure; type 4: hypoplastic death; type 5: early death; type 6: 
extramedullary leukemic persistence. 
Extraction 
A. Low-volume extraction. Borate buffer (0.2 ml; 0.5 M, pH 9.8) and 2 ml extraction 
mixture (chloroform: methanol4:1) were added to 2.0 ml cell suspension in a 
siliconized tube. The tubes were closed with silicone corks and vortexed for 2 
min. After centrifugation at 1000 g for 10 min, 100 fll of the lower organic layer 
were injected into the column. 
B. High-volume extraction. Borate buffer (0.2 ml; 0.5 M, pH 9.8) and 5 ml extraction 
mixture were added to 2.0 mlleukocyte suspension in a 30-ml glass bottle and 
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shaken for 20 min at 300 rpm on a Mini-shaker (MSR, Salm and Kipp, Breukelen, 
Holland) in the dark. After this, 1 ml of the organic phase was dried with a 
gentle stream of nitrogen. Dried samples were reconstituted with 300 Ill 
chloroform: methanol (4:1) and 100-i.J.l aliquots were then analyzed by HPLC. 
The patient plasma samples were extracted using the low-volume extraction 
technique, and the whole blood and leukocyte samples were extracted using the 
high-volume extraction method, with DOX added as internal standard. 
High-performance liquid chromatography (HPLC) 
HPLC separation (adapted from Baurain et al. (2)) was accomplished using a Waters 
Associates M-510 pump and a Waters Associates automatic sample injector (Model 
710B). The stationary phase consisted of 7-IJ.m silica gel particles prepacked into a 
250 x 4.6 mm stainless steel column (Lichrosorb Si-60-7, Chrompack). The mobile 
phase consisted of chloroform, methanol, acetic acid, water and 3 mM MgCb 
solution in water (720:210:40:24:6 by volume), filtered (Millipore FH 0.5 IJ.m) and 
used at a flow rate of 0.8 ml/min. Fluorescent detection was accomplished using a 
Gilson Spectra-Glo fluorometer at 480 and 560 nm for the excitation and emission 
wavelengths, respectively, and equipped with a 45-i.J.l flow cell. The integration of 
the peak areas was performed by a Shimadzu Model CR3A integrator (United 
Technologies Packard, Delft, Holland). 
The linearity and sensitivity of the method were determined from serial 
concentrations of DNR, DOL and DOX in chloroform: methanol (4:1). Linear 
calibrations were obtained for all three compounds in the concentration range of 
12.5-400 ng/ml (Fig. 1) (coefficient of variation 5%-7% at 50 ng/ml). The lower 
detection limit of DNR in plasma was 5 ng per injection of 100 i.J.l and after 
extraction from biological fluids, 25 ng/ml biological fluid or 5 IJ.g/109 leukocytes. 
Mathematical modeling 
The data from the seven AML patients were analyzed by fitting a two-compartment 
model to the observed plasma and intracellular DNR concentrations (15). The first 
(central) compartment represents the plasma distribution of DNR. The second 
(peripheral) compartment represents the concentration-time curves of DNR in 
tissues, including the cellular elements in blood. The plasma and intracellular 
concentration-time disappearance of the parent drug (DNR) are described by the 
following equations, respectively: 
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C(t) = A . e-a.t + B . e-~.t (1) 
C(t) = A. ( e-~.t - e-a.t) (2) 
where C(t) is the plasma (Eq. 1) or intracellular (Eq. 2) level of DNR at each timet 
after the injection, A and B are constants, and a and ~ are first-order elimination 
rate constants. 
The DNR area under the concentration-time curves (AUC) in plasma and leukocytes, 
the volume of the central (plasma) compartment (V1), the apparent distribution 
volume (Vdarea) and the plasma clearance (Cl) were calculated from this model. 
Results 
Separation of human leukocytes 
For determination of DNR and DOL concentrations attained in vivo in leukemic cells 
of AML patients, it is necessary to use a separation method which provides pure 
leukocyte fractions without contamination of erythrocytes or selective loss of 
leukocytes. The separation was performed at 0-4 ·c, to prevent metabolism of DNR 
(16). Other possible degradation of DNR was avoided by working in reduced daylight 
and using siliconized tubes (17,18). We compared two procedures for cell separation. 
In the first place, methylcellulose was used for sedimentation of leukocytes. 
Secondly, using the lysis buffer, the leukocytes were isolated following hypotonic 
lysis of the erythrocytes. The recoveries of the leukocytes and erythrocytes were 
expressed relative to the total number of leukocytes and erythrocytes before 
separation (set at 100%). The leukocyte purification factor designates the ratio of the 
percentage recovery of leukocytes in the leukocyte pellet and in the whole blood 
sample. 
Table 1: 
Recove.-ies of leukocytes and eryth.-ocytes in human leukocyte pellets aftel" 
sepal"ationa 
Separation Nb Recovery of Recovery of Leukocyte 
method leukocytes (%) erythrocytes (%) purification 
(mean ±SD) (mean ±SD) factor 
(mean ±SE)c 
Methylcellulose 86 65 ±24 3 ±3 66 ± 15 
Lysis buffer 67 106 ± 16 2 ±3 490 ± 102 
a: Before separation the leukocyte concentration of the blood samples varied from 0.25 
to 170 x I 09 cells/! (set at I 00%) 
b: Number of experiments 
c: The leukocyte purification factor designates the ratio of the percentage recovery of 
leukocytes in the leukocyte pellet and in the whole blood sample 
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As is shown in Table 1, the recovery of leukocytes after hypotonic lysis was complete 
(106%) and superior to that after methylcellulose separation (65%). The recovery of 
erythrocytes was equivalent with both methods (2%-3%), which indicates almost 
complete removal of erythrocytes from the leukocyte pellets after separation with 
either method. In further experiments we used hypotonic lysis for cell separation. 
Table 2: 
Patient characteristics 
Patient Sex Age FAB WBC % Blasts Dose of Dose of Number Outcome 
classi- (x 109/1) in DNR. DNR. (mg) of of 
fication at initial peripheral (mg!m2) induction remission 
diagnosis blood at courses induction 
initial therapy 
diagnosis 
M 42 Ml 1.44 7 45 75 2 CR 
2 M 73 Ml 13.0 75 45 80 I CR 
3 F 65 Ml 1.406 0 45 70 2 CR 
4 M 45 M4 4.1 84 45 90 2 PR 
5 M 37 M4 107.3 76 45 90 2 PR 
6 M 26 M4 170.0 99 45 80 2 PR 
7 M 17 M2 6.5 79 45 80 2 Type I 
failure 
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Recovery of DNR, DOL, and DOX after extraction from leukocytes 
Low-volume extraction of DNR, DOL and DOX from biological samples, such as 
plasma and urine, yields recoveries of approximately 100% (2,3). When this 
extraction method is applied to biological samples containing variable 
concentrations of cells, it appears that the recoveries of DNR, DOL, and DOX depend 
on the cellularity of the extracted sample, regardless of the amount of drug added to 
the cells. As shown in Fig. 2A, the recovery of DOX is very low compared with that 
of DNR and DOL, especially in samples with large amounts of cells. Since DOX has 
been added as an internal standard for the quantification of DNR and DOL, better 
recovery is necessary. 
Large-volume extraction with a long period of extraction gives better recoveries of 
DNR, DOL, and DOX (Fig. 2B). Nevertheless, again the recovery of DOX is lower than 
that of DNR and DOL. The recovery of all drugs depends on the cellularity of the 
sample. These results indicate that determination of the DNR content of human 
leukocytes may be subject to variation, depending on the method of isolation, the 
volume and duration of extraction, and the cell concentration of the suspension. 
Pharmacokinetics of DNR in AML patients 
Table 2 shows certain characteristics of seven previously untreated patients with 
AML. At diagnosis a large variation in the number of peripheral white blood cells 
(WBC) was apparent (range 1.4-170 x 109 cells/1). For calculation of DNR in whole 
blood and in leukocytes, correction factors were used to account for the cellularity of 
the samples. As shown in Fig. 3, the plasma concentrations of DNR rapidly declined 
to minimal or undetectable levels within +4 h to +8 h after administration. This 
rapid decline was associated with the appearance of the major metabolite DOL in the 
plasma. Generally, DOL plasma concentrations exceeded DNR levels within +1 h 
after administration, and at +4 h after administration the DOL concentration was 
80% or more of the total amount of detectable anthracycline (data not shown). With 
our method of drug determination no metabolites other than DOL were found. 
In Fig. 4 the whole blood concentration-time curves of DNR are shown. When they 
are compared with those for plasma, it is obvious that a more variable decline can 
be observed. At +4 h after administration of the drug two patients had high DNR 
(60%) and DOL (40%) blood levels, while the other patients had low or undetectable 
levels. 
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DNR accumulated extensively in the leukocytes, at concentrations which were even 
more variable than those in plasma and blood (Fig. 5). Maximum cellular DNR 
concentrations were reached almost immediately after administration of the drug in 
all patients. Intracellular DOL was present at much lower concentrations than in 
plasma (20%). 
Tables 3 and 4 show the calculated plasma and cellular pharmacokinetic parameters 
of DNR in these seven AML patients. Clearly, the wide interindividual variation in 
the AUCs for DNR in leukocytes is not reflected by the AUCs in plasma of the same 
patients. Thus, the data suggest that the leukocytes should be regarded as a separate 
compartment. 
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Fig. 5: 
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Table 3: 
Plasma pharmacokinetic parameters of daunorubicin in AML patients after IV 
bolus injection at t=O 
Patient t112a tl/2fl Via 
(h) (h) (x I 000 I) 
0.07 1.04 0.12 
2 0.07 0.77 0.23 
3 0.07 2.17 0.13 
4 0.10 0.48 0.12 
5 0.18 0.81 0.60 
6 0.02 0.61 0.01 
7 0.01 0.76 0.01 
a: Volume of the central (plasma) compartment 
b: Apparent distribution volume 
c: Plasma clearance 
Table 4: 
Vdarea b Clsc 
(x I 000 I) (x I 000 1/h) 
0.57 0.38 
0.34 0.31 
0.64 0.20 
0.32 0.47 
0.74 0.46 
0.25 0.28 
0.33 0.30 
Area under the plasma and leukocyte concentration-time curves {AUC} for 
daunorubicin in AML patients after IV bolus injection at t=O 
Patient 0-4 h 0-8 h 0-24 h 0-oo h 
Plasma AUC (nmol x h/ml) 
I 0.35 0.37 0.37 0.37 
2 0.47 0.49 0.49 0.49 
3 0.49 0.61 0.65 0.65 
4 0.36 0.36 0.36 0.36 
5 0.27 0.27 0.27 0.27 
6 0.54 0.54 0.54 0.54 
7 0.50 0.51 0.51 0.51 
Leukocyte AUC {nmol X h/I O' cells) 
I 4.61 4.61 4.61 4.61 
2 33.61 44.72 50.02 50.07 
3 175.20 175.43 175.43 175.43 
4 60.83 82.92 95.28 95.48 
5 104.04 158.67 214.41 218.95 
6 106.88 157.34 199.94 202.10 
7 24.81 26.14 26.21 26.21 
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Discussion 
For better understanding of the wide variation in individual response to DNR in 
AML, individual drug monitoring in the leukemic cells is of interest. Therefore, we 
decided to develop an efficient and reliable method that would be useful for 
measuring concentrations of DNR and DOL in the cells of AML patients. 
Methylcellulose or Ficoll-Isopaque are frequently used for separation of leukocytes. 
We found that the recovery of leukocytes after methylcellulose separation when 
applied at 0-4 ·cis low (64%), which is most likely due to the relatively low 
temperature used for the procedure. At 0-4 ·c methylcellulose is a gel with increased 
viscosity, which may interfere with proper separation of blood cells (6). At 20 ·c 
methylcellulose forms a colloid solution, and at this temperature the recovery of 
leukocytes is better (95%). Obviously, this temperature, although permitting 
satisfactory cell recoveries, has the disadvantage of being associated with the 
metabolic degradation of DNR to DOL by aldoketoreductase, an enzyme which is 
present in leukocytes and in myeloblasts (9,10). Cold hypotonic lysis gave clearly 
superior results. It could be performed at 0-4 ·c, with excellent separation of white 
and red blood cells and 100% recovery of all nucleated cells. 
The extraction method is shown also to be critical. The recovery of DNR depends on 
the volume of extraction and the duration of extraction (Fig. 2A, B). Owing to the 
use of large volumes in bottles, the surface exposures of the two liquid phases are 
increased and a better transfer of the drugs into the organic phase is obtained. 
Extraction times up to 20 min improved drug recoveries, but extractions beyond 
20 min did not contribute further. 
Even under conditions of optimal cell isolation and drug extraction the recoveries of 
DNR and DOX remain dependent on the cellularity of the sample. This is the case 
irrespective of the amount of drug in the cells. Thus, the number of cells submitted 
to extraction is inversely related to the fraction of intracellular DNR and added DOX 
to enter the organic phase. In other words, the number of leukocytes correlates 
negatively with the partition coefficients of DNR and DOX. It remains to be 
determined whether this is caused by fractional binding of the drugs to cell 
fragments, or whether the cell fragments mechanically prevent a proper exchange of 
the drug molecules between the two liquid phases. In calculations of the DNR 
content of leukocytes, it is therefore still necessary to correct for cellularity of the 
sample. This correction factor is variable and is derived from the concentration of 
cells in the sample. It might be that excessive denaturation of DNA, for example by 
pretreatment with silver nitrate, improves the extraction ratio of DNR from DNA 
binding sites. To avoid heterogenous recoveries from different samples, we 
standardized the patient blood samples and leukocytes with PBS at final 
concentrations between 1 and 10 x 109 cells/1 before starting on the extraction 
procedure. 
With the above-defined criteria it is possible to monitor the in vivo plasma and 
cellular pharmacokinetics of DNR and DOL in patients in a reproducible way during 
treatment. In the small series of patients with AML treated with DNR during 
remission induction and with variable numbers of circulating leukemic cells, it was 
found that: 
1) plasma levels of DNR and DOL do not correlate with blood and leukocyte 
concentrations of DNR and DOL; 
34 
2) plasma pharmacokmetic parameters do not correlate with cellular 
pharmacokinetic parameters; 
3) in vivo cellular levels of DNR are considerably more variable than in vivo DNR 
levels in plasma or whole blood; 
4) the pattern of DNR metabolism is different in the leukocytes and the plasma. 
Although these conclusions are based on a small number of patients, they 
demonstrate that the plasma concentration of DNR and DOL provides little 
information on the drug concentrations attained in the leukocytes. These findings 
are in agreement with the results of DeGregorio et al. (6), who indicated that plasma 
concentrations of DNR and DOL were not useful for estimation of the in vitro 
inhibition of DNA synthesis. Our findings are also consistent with the conclusion of 
Preisler et al. (13), who showed that there was no significant correlation between 
plasma levels of anthracyclines and clinical response to therapy in patients with 
AML. Therefore, to analyze the clinical effectiveness of DNR it may be useful to 
pursue the pharmacokinetics of DNR and metabolites not only in plasma but 
particularly in leukocytes in blood and bone marrow. 
It remains to be investigated whether the determinations of drug concentrations in 
the leukocytes will indeed provide prognostic indicators of the variable outcome of 
remission induction therapy and the duration of complete remission in acute 
leukemia patients. As yet, our studies described here may be of use to set a 
methodological baseline for these approaches. 
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CHAPI'ER3 
Comparative studies of the in vitro 
uptake of daunorubicin by human 
hemopoietic cells and nuclei measured 
by flow cytometry and HPLC 
Parts of this chapter (in vitro data) combined with Chapter 6 (in vivo data) are based 
on investigations published in: 
Leukemia 2:511-517, 1988 
Esther Kokenberg, Pieter Sonneveld, Ruud Delwel, Willemijn Sizoo, Anton 
Hagenbeek and Bob LOwenberg 
In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by 
flow cytometry 
Abstract 
The major white cell subpopulations present in bone marrow and blood can be 
discriminated by forward and perpendicular light scatter two parameter flow 
cytometry. Fluorescent properties of daunorubicin (DNR) allow measurement of the 
concentration of this drug in hematopoietic cells by flow cytometry as a third 
parameter. We evaluated the applicability of flow cytometry for measuring DNR 
uptake in direct comparison with high performance liquid chromatography (HPLC). 
In vitro studies revealed good correlations between the mean cellular and nuclear 
fluorescence measured by flow cytometry and the cellular and nuclear DNR 
concentrations determined with HPLC. In addition, !t was shown that the nuclear 
DNR associated fluorescence involved DNR bound to the nucleus rather than free 
DNR. 
Introduction 
The pharmacokinetics of anthracyclines in plasma of AML patients studied with thin 
layer chromatography (1,2) and high-performance liquid chromatography (HPLC) 
(3,4), show that the anthracyclines accumulate rapidly in the tissues outside the 
plasma compartment. Studies with cell lines have shown that most anthracyclines, 
including daunorubicin (DNR), accumulate almost exclusively in the nucleus (5), as 
was to be expected from the high binding constants of these agents for DNA (6). 
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However, data on cellular anthracycline concentrations in human cells after in vivo 
administration are scarce (7 ,8). With HPLC this information can be obtained. 
However, the HPLC method is laborious and does not provide insight into 
antbracycline concentrations present in different subpopulations of cells, e.g., 
normal hematopoietic cells versus leukemic cells. With flow cytometry the cellular 
drug fluorescence can be determined as a function of subpopulations of cells. On the 
other hand a disadvantage of flow cytometric measurements is the apparently 
reduced fluorescence of DNR, once the drug is bound to DNA of intact cells. This 
effect is called quenching of fluorescence emission (9,10). Therefore, in the present 
report we have analyzed whether the DNR associated fluorescence as measured with 
flow cytometry is: 
a) linearly related to the DNR content of cells and 
b) represents the total cellular (i.e., cytoplasm and nuclear) DNR content of cells. 
After flow cytometric measurements, quantitation of the DNR content of the same 
cells was done by HPLC analysis. Following this approach we wanted to evaluate the 
applicability of flow cytometry for measuring DNR concentrations in leukemic cells 
in vivo. 
Materials and methods 
Anthracyclines 
Daunorubicin and doxorubicin were obtained as the commercial preparations 
Cerubidine (Rhone-Poulenc, Paris, France) and Adriablastina (Farmitalia Carlo 
Erba, Milan, Italy), respectively. The drugs were dissolved in methanol, diluted in 
water and stored at -20 ·c as 200 J.Lg/ml stock solutions. Aliquots were thawed as 
required and diluted appropriately with water. 
Collection and isolation of normal WBC 
White blood cells (WBC) suspensions were prepared from huffy coats from healthy 
donors, which were obtained as a side product following single donor platelet 
pheresis (Aminco, Celtrifuge 1), with ACD-A as anticoagulant. The huffy coat cells 
were washed with phosphate buffered saline (PBS) (450 g, 10 min) to remove the 
plasma, and depleted of erythrocytes and normoblasts following cold hypotonic lysis 
(11). Then, the WBC were harvested, washed two times with PBS, counted and finally 
the WBC were resuspended at a concentration of 10 x 109 cells/1 RPMI medium 
(pH 7.2). 
Incubation of WBC with DNR 
For the measurements of DNR in whole cells, DNR was added to 1.5 ml of the WBC 
suspension at final concentrations ranging from 8 up to 150 nmoV109 cells. For the 
measurements of DNR in nuclei, WBC (24 x 106 cells in 3 ml) were incubated in 
duplicate with two different DNR concentrations (i.e., 120 nmoV109 cells and 60 
nmoV109 cells). In addition, in order to determine the DNR leakage from nuclei, WBC 
(200 x 106 cells in 20 ml) were incubated with DNR at a final concentration of 190 
nmoV109 cells. A blank sample (unstained cells) was used in parallel incubations in 
order to measure background fluorescence. The cells were incubated in a shaking 
water bath at 37 ·c for 30 min. After incubation the cells were put on melting ice 
and washed two times by centrifugation (450 g, 10 min, 4 "C) ,and resuspension of the 
pellets in ice cold RPMI. Finally, the cells were resuspended in PBS and counted. 
Parts of the cell suspensions were stored at -20 ·c until analysis with HPLC, other 
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parts were kept on ice and used for determination of the cellular DNR concentration 
with flow cytometry, while the rest of the cells was used for isolation of nuclei. 
Isolation of nuclei 
The cells were centrifuged, resuspended in buffer (3.0 mM MgCh, 1.0 mM 
monothioglycerol, 250 mM sucrose, 1(fmM Tris-HCl, pH 7.7, 0.2% (v/v) Triton 
X-100) and fractionated by Dounce homogenization (12). The nuclei were washed 
two times (600 g, 15 min, 4 "C), resuspended and counted. Microscopic examination 
showed that most nuclei were in tact. Part of the suspension was stored at -20 ·c for 
HPLC measurement and part was used for flow cytometric determination of the 
nuclear DNR concentration. The cytosol fractions were also stored at -20 ·c for HPLC 
measurements. 
Measurement of DNR leakage from nuclei 
The nuclei were resuspended in 30 ml buffer (3.0 mM MgCl2, 1.0 mM 
monothioglycerol, 250 mM sucrose, 10 mM Tris-HCl, pH 7.7) and dialyzed against a 
great volume (1liter) of the same buffer. At several time intervals (at 0, +10, +20, 
+30, +45, +60 min as well as at +1.5, +2, +2.5 and +3h after start of dialysis) a sample 
of the suspension of nuclei was analysed for DNR associated fluorescence by flow 
cytometry and HPLC. 
Measurement of cellular and nuclear DNR content by flow cytometry 
The fluorescent properties of DNR permitted measurement of DNR content of 
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Correlation of DNR incubation 
concentrations with mean cellular 
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Data of four incubation experiments with 
identical incubation conditions 
(i.e., IS x I Q6 cells/1.5 ml RPM I, incubated 
at 37 ·c for 30 min) (n = 29). 
individual cells/nuclei with a Becton-Dickinson (Mountain View, CA) fluorescence 
activated cell sorter (FACS 440). In the FACS 440 system the cells/nuclei traverse the 
light beam of a Spectra-Physics 5 W argon laser tuned at 488 nm, 0.4 W, which is 
close to the absorption maximum of DNR. The fluorescence emitted by the cells/ 
nuclei upon excitation by the laser light is registered on a photomultiplier. The 
scatter light was blocked with a 550 nm long-pass glass filter. The signals from the 
photomultiplier were linearly amplified. The instrument was calibrated with 1.0 and 
2.83 fl diameter fluorescent standard beads (Polysciences Inc., Warrington, PA). The 
forward and perpendicular light scatter from the cells/nuclei were measured on 
separate detectors. The intensities of these signals, which are determined by cell size 
and cell structure respectively, were used to distinguish the different cell types in 
WBC or in bone marrow (13). For each sample, at least 10 x 103 cells/nuclei were 
analysed at a flow rate of 1-2 x 103 cells/sec. Cell debris were excluded from 
analysis by elevating the threshold of the forward light scatter. The scatter signals 
from the nuclei were quite homogeneous so that no subpopulations of nuclei could 
be distinguished (Fig. 1). 
Data analysis was performed using a Hewlett Packard 68B system. Fluorescent 
profiles were recorded as histograms of fluorescence intensity versus cell/nuclei 
frequency. The relative value of DNR fluorescence was obtained for each population 
by calculating the mean of the fluorescence distribution. Mean fluorescence was 
expressed in arbitrary units, taking into account the blank samples that were used to 
correct for background fluorescence (subtraction of blank values). 
Analysis of cellular and nuclear DNR and daunorubicinol by HPLC 
Concentrations of DNR and its major metabolite daunorubicinol (DOL) were 
determined using straight-phase HPLC analysis as described previously (11,14,15). 
For drug quantification, doxorubicin was used as an internal standard. 
Statistics 
The Spearman test was used for calculating correlation coefficients. 
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Results 
Recovery of nuclei and DNR after isolation of nuclei from WBC 
The recoveries of nuclei isolated from the cells were expressed relative to the total 
number of nucleated cells before isolation and appeared almost complete (mean 
94%; Table 1). The recoveries of DNR in nuclei and cytosol after cellular 
fractionation, as shown in Table 1, were almost complete as well (mean 97%), which 
ruled out loss of nuclei or DNR during the isolation procedure. 
Correlation of flow cytometry with HPLC 
Measurements in whole cells (white blood cells). 
Normal WBC were incubated (at 37 'C, 30 min) with varying DNR concentrations 
ranging from 8 to 150 nmoV109 cells. After incubation the cellular fluorescence of 
Table 1: 
Recoveries of nuclei and nuclear and cytosolic DNR in human leukocyte 
pellets after cellular fractionation 
Sample number Incubation Recovery of nuclei Recovery of DNR in 
concentration (nmol (%)a nuclei and cytosol 
DNRII 09 cells) (%)b 
120 92 95 
2 120 100 84 
3 60 88 128 
4 60 83 81 
a: Nuclei before isolation represents I 00%. 
b: Values relative to cellular concentrations of DNR, as determined with HPLC (I 00%). 
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10 x 10 3cells was measured by flow cytometry. A positive relationship was observed 
between the extracellular DNR concentrations in the incubation medium and the 
mean cellular fluorescence (p < 0.001, Fig. 2). A portion of the cells were used for 
determination of the cellular DNR and DOL contents by HPLC. Approximately 70% 
of DNR had been taken up by the cells during the 30 min drug exposure time from 
the incubation medium. Flow cytometry does not distinguish between the parent 
drug (DNR} and the metabolite DOL. However, with HPLC analysis no detectable 
amounts of cellular DOL were found. This indicates that cellular metabolites had 
contributed a negligible amount to the total fluorescence (assessed with flow 
cytometry) at the concentrations applied. 
The mean cellular fluorescence as measured with flow cytometry was compared with 
the amount of DNR measured following extraction and HPLC. These two 
measurements correlated well (p < 0.001, Fig. 3), indicating that flow cytometric data 
Table 2: 
Nuclear drug concentration in normal human leukocytes determined with 
HPLC and flow cytometry 
Sample number Incubation HPLC nuclear Flow cytometry 
concentration (nmol amount of DNR (%)a nuclear amount of 
DNR/1 09 cells) DNR (%)a 
120 56 60 
2 120 49 55 
3 60 59 45 
4 60 45 38 
a: Values relative to total cellular DNR concentration (I 00%). 
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Concentration-time course of DNR in 
nuclei isolated from normal human 
leukocytes after in vitro incubation 
of the cells with DNR 
The nuclei were dialyzed against a DNR 
free buffer. The DNR concentration is 
expressed relative to the concentration at 
start of the dialysis which was set at I 00%. 
provide a good quantitative measure of cellular drug content. The DNR related 
fluorescence signals obtained from the cells incubated with a range of DNR 
concentrations in vitro were intense and easily detectable with flow cytometry. From 
Figs. 2 and 3 it appears that the fluorescence intensity after incubation with the 
lowest DNR concentration (8 nmol DNR/109 cells) approached the detection limit. 
When concentrations of DNR in these cells were subsequently determined with HPLC, 
only small peaks (about 6 nmol DNR/109 cells) were observed in the chromatograms. 
Measurements in nuclei. 
Isolated WBC were incubated with two different DNR concentrations: 60 nmol and 
120 nmol/109 cells. After isolation of the nuclei, cellular and nuclear fluorescence 
were measured by flow cytometry and HPLC. With flow cytometry the fluorescence 
signals from the cells as well as from the nuclei were easily detectable. The nucleus/ 
whole cell ratios of DNR as determined with flow cytometry or HPLC were 
concordant (Table 2). Under these experimental conditions about 50% of DNR was 
associated with the nucleus, regardless the incubation concentration used. 
In addition, the DNR related fluorescence signals obtained from the cells and nuclei 
correlated well (p < 0.001) with the absolute amount of DNR measured after chemical 
extraction and chromatography (Fig. 4). Thus, flow cytometry does not only provide 
a good quantitative measure of cellular but also of nuclear DNR content. 
Leakage of DNR from nuclei 
We first determined whether the nuclear DNR measured with flow cytometry was 
free DNR in the nucleus or DNR really bound to DNA. Therefore, DNR containing 
nuclei were dialyzed against DNR free buffer. The concentration of DNR in the nuclei 
at start of the dialysis was determined with flow cytometry (set at 100%). The 
nuclear concentration of DNR determined at several time intervals after start of 
dialysis is shown in Fig. 5 and is expressed relative to the concentration before 
dialysis. These data indicate that during the first 1.5 h after start of dialysis the 
nuclear drug level is stable, but after that time the nuclear drug level rapidly falls to 
a low level. The same samples were also analysed with HPLC showing identical 
concentration-time data. In addition, the fall in the DNR level was associated with 
an increase in nuclear fragmentation as was evident from microscopic examination. 
Thus, after a stable period of 1.5 h of dialysis, DNR associated fluorescence per 
nucleus had declined and the nuclei began to desintegrate. 
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Discussion 
The main advantage of flow cytometry compared with the traditional methods of 
estimation of cellular levels of anthracyclines relates to the possibility to identify 
subpopulations of (hematopoietic) cells. Also it is possible to identify and therefore 
exclude, any dead cells or cell debris which may contaminate the cell mixture and 
interfere with the estimation (16). However, when flow cytometry is used for 
quantifying the cellular DNR concentrations, the cellular fluorescence caused by 
DNR is said to be influenced by quenching when the drug is intercalated in DNA 
(9,10). In such instances conventional methods such as HPLC analysis are needed to 
validate the flow cytometry methodology. Therefore we compared the cellular DNR 
associated fluorescence with the DNR content of human nucleated cells as measured 
withHPLC. 
The incubation concentrations of DNR were low in comparison to the concentrations 
used by others (8,16-20) but were deliberately chosen in order that resulting cellular 
concentrations in vitro correspond to those attained in vivo in WBC and bone 
marrow cells in patients on treatment with DNR (11,14). Like others (16,21-23) we 
found a positive correlation between the extracellular DNR concentrations and the 
resulting mean fluorescence following incubation in vitro. In addition, we showed 
good correlations between the mean cellular fluorescence and the amount of DNR 
taken up by the cells in vitro. Further, the detection level of flow cytometry 
appeared comparable to that of HPLC. Our data are in agreement with results of 
previous reports indicating concordances between flow cytometric and fluorometric 
analysis to quantitate cellular anthracyclines (18,20,24) and between fluorescence 
and cellular content of radiolabeled DNR (16). 
The results of the DNR concentrations determined in nuclei versus whole cells 
indicate that flow cytometry data provide a measure of total cellular DNR content: 
DNR fluorescence originating from the cytoplasm and from the nucleus. However, 
since it was not known to what extent the nuclear DNR measured with flow 
cytometry was free or nuclear bound, we determined the leakage of DNR from the 
nuclei. The leakage experiment showed that DNR remained tightly bound in the 
nuclei for a stable period of 1.5 h. After that time, the nuclei began to desintegrate 
and the DNR was quickly released into the DNR free buffer. These results indicate 
that the nuclear DNR associated fluorescence as measured with flow cytometry 
involves DNR bound to the nucleus rather than free DNR. The available evidence 
thus supports the conclusion that flow cytometric measurements of cellular DNR 
fluorescence can be considered as a good quantitative measure of total cellular drug 
content, including nuclear bound DNR. 
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Abstract 
The capability of nucleated blood cells and leukemic cells to transport daunomycin 
(DNR) to target tissues in the body was investigated in the rat. The in vivo 
distribution kinetics of DNR entrapped in leukemia cells (brown Norway acute 
myeloid leukemia, BNML) or in nucleated bone marrow cells, which had been 
exposed to DNR (0.2 mg/5 x 107 cells) in vitro, were determined. It was found that 
BNML leukemia cells and normal bone marrow cells take up DNR according to a 
linear pattern up to 400 J.Lg/5 x 107 cells. When these DNR loaded cells are infused 
into the rat, dose dependent distribution kinetics are observed. Compared to IV 
injection of the same dosage, cell-bound DNR leads to a higher concentration and a 
higher tissue area under the curve of DNR in the liver (p < 0.05) and the spleen (p < 
0.05), while equal levels are attained in bone marrow. Lower concentrations and 
area under the curve of DNR are observed in cardiac tissue of normal rats (p < 0.001) 
and leukemic rats (p < 0.05). It is concluded that DNR entrapped into marrow and 
leukemia cells follows different kinetics from free DNR in plasma. 
Introduction 
The anthracycline antibiotic daunomycin (DNR) is a prominent drug for the 
remission-induction and consolidation therapy of acute myelocytic leukemia. The 
toxicity of this drug is considerable and includes bone marrow depression, alopecia 
and cardiotoxicity (1). It has been known for some time that the rapid decline of 
plasma concentrations may be attributed to the conversion of DNR to its major 
metabolite daunorubicinol (DOL) and to uptake of the drug by many tissues, 
including leukemic cells (2-6). We have previously reported the distribution kinetics 
of DNR in the rat following different dosages and schedules of administration (7-9). 
From these data it appears that intracellular levels of DNR exceed plasma levels 
after the initial distribution phase. Thus, intracellular DNR levels may better 
correlate with the target tissue effect. 
In the present study we have examined the distribution of DNR carried by leukemic 
cells in vivo, and compared it with DNR carried in normal bone marrow nucleated 
cells and with the normal plasma distribution of DNR. The purpose of this study is to 
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determine to what extent the nucleated cells add to the transport of DNR to target 
tissues in acute leukemia. 
Materials and methods 
Chemicals 
Daunomycin, daunomycinol and Adriamycin were supplied by Farmitalia (Milan, 
Italy). Chromatographic assays were performed with HPLC quality reagents, 
purchased from Baker Chemicals (Holland). 
Animals 
Twelve-week-old female barrier derived inbred brown Norway (BN/BiRij) rats raised 
in the inbred Rijswijk colony were used. At the time of the experiments their body 
weight averaged 150-200 grams. 
Leukemia model 
The brown Norway myeloid leukemia (BNML) was chosen as a model. This acute 
myelocytic leukemia originated in 1971 in a female rat of the inbred brown Norway 
rat strain in the Rijswijk colony (BN/BiRij) following three intravenous (IV) 
injections of 2 mg of 9,10-dimethyl-1,2-benzanthracene 100 days earlier. The 
leukemia has since been maintained by transplantation of leukemic cells directly or 
by cryopreserved batches. The characteristics of BNML have been described 
extensively (10) and can be summarized as follows: 
1) the growth fraction is low, with an increased cell loss rate as the terminal stage 
of the disease approaches. This leads to a relatively low net cell production rate; 
2) it is cytochemically and cytologically identical to human acute myeloid leukemia 
(AML); 
3) the mean survival time after IV inoculation of 107 leukemic spleen cells is 22 days; 
4) the response to DNR and other cytostatic drugs is comparable with that of human 
AML patients. 
The experiments with leukemic animals were performed in BN rats inoculated with 
leukemia, at a stage of the disease comparable with that of human AML patients at 
clinical admission (day 14 after IV transplantation of 107 leukemic spleen cells). At 
this stage, many organs such as the spleen, liver, lungs and bone marrow are heavily 
infiltrated by leukemic cells. 
Incubation of cells 
Normal rat nucleated bone marrow cells were harvested from the femurs of 
untreated rats as described previously (11). Fifty million nucleated bone marrow 
cells in 1 ml RPMI medium+ 5% fetal calf serum (pH 7.4) were incubated for 20 min 
at 37 ·c with DNR concentrations of 0.2, 0.4, 0.6, 0.8 and 1.0 mg/ml. 
After incubation, the cells were put on melting ice and washed twice by 
centrifugation (400 gat 4 "C) and the pellets resuspended in ice cold RPMI. Finally, 
the cells were resuspended in 1 ml RPMI. The concentration of DNR in the cells was 
determined by chemical extraction and liquid chromatography as described below. 
No measurable loss of intracellular drug from the cells to the extracellular drug-free 
medium could be observed in cells which had been incubated with DNR and stored 
at 4 ·c for maximally 1 hr. 
Subsequently the DNR-containing cells were injected into a tail vein of a rat at a 
final volume of 1 ml (5 x 107 cells/ml). 
48 
BNML leukemia cells were obtained from the spleen of a rat which had been 
inoculated with leukemia cells 17 days before, as described earlier (12). Leukemic 
cells were incubated with DNR in the same way as normal bone marrow cells. After 
the incubation and the washing procedures had been completed, 5 x 107 leukemic 
cells in 1 ml of RPM! buffer were injected into the tail vein of leukemic rats at 
day 14 after they had been inoculated with BNML leukemia. 
In addition, one group of normal BN/BiRij rats and one group of leukemic BN/BiRij 
rats at day 14 of the disease were treated IV with a single bolus injection of DNR at a 
dosage which was identical to the amount of drug administered when entrapped in 
cells. After administration of DNR rats were killed by exsanguination at + 30 min, 
+1 h, +4 hand +24 h. Each treatment group consisted of three rats at each time 
interval. To obtain bone marrow cells, a femur was cut into two parts and each part 
was repeatedly flushed with 2 ml of saline. Femoral bone marrow, the liver, the 
spleen and the heart were taken out, washed and immediately frozen at -20 ·c until 
further processing. Plasma was obtained by adding citrate to aortic artery blood 
samples. 
Drug assay 
Daunomycin and daunomycinol (DOL) concentrations were determined by straight 
phase high pressure liquid chromatography. Plasma samples adjusted to pH 9.8 were 
extracted with a chloroform-methanol (4:1) mixture. After centrifugation, 1 ml of the 
organic phase was evaporated to dryness under nitrogen at 30 ·c. The residue was 
redissolved in 300 J.1l mobile phase. Ten percent homogenates of tissues in NaCl 
(0.9%), were adjusted to pH 9.8 and extracted with a chloroform-methanol (4:1) 
mixture. One hundred microliter aliquots of the organic phases were injected 
directly on the column. Two milliliters of the bone marrow suspension were adjusted 
to pH 9.8 and thereafter extracted with chloroform-methanol (4:1). For plasma, the 
recovery of the extraction procedure was 90-95%. For tissues, the recovery was 
85-90%. Adriamycin was used as an internal standard for drug quantification. 
HPLC separation (adapted from Baurain et al. (13)) was accomplished using a Waters 
Associates M-510 pump and a Waters Associates automatic sample injector (Model 
710B). The stationary phase consisted of 7-~m silica gel particles prepacked into a 
250 x 4.6 mm stainless steel column (Lichrosorb Si-60-7, Chrompack). The mobile 
phase consisting of chloroform, methanol, acetic acid, water and 3 mM MgCh 
solution in water (720:210:40:24:6 by volume) was filtered (Millipore FH 0.5 ~m) and 
used at a flow rate of 0.8 ml/min. Fluorescence detection was accomplished using a 
Gilson Spectra-Glo fluorometer at 480 and 550 nm (cut-off filter) for the excitation 
and emission wavelengths, respectively, equipped with a 15 J.1l flow cell. 
The lower limit of detection of DNR and DOL was 10 ng/ml (plasma) and 10-20 ng/g 
(tissue). 
Calculations 
The trapezoidal method was used for the calculation of the tissue area under the 
curve (AUC) from zero to +4 h after drug administration. The Spearman correlation 
test, linear regression and the Wilcoxon test were used for statistical analysis. 
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Results 
Fig. 1: 
Intracellular concentration of DNR in 
normal rat BN bone marrow cells 
{e-e) and BNML rat spleen leukemia 
cells {0-0) following an incubation 
period of lO min with different 
extracellular concentrations of DNR 
Spearman correlation coefficients: 
BN: 0.98 (p < 0.00 I); 
BNML: 0.99 (p < 0.00 1). 
Upon incubation of rat bone marrow nucleated cells with DNR the uptake of the 
drug depends on the extracellular drug concentration (p < 0.001) (Fig. 1). Also, when 
BNML leukemia cells instead of bone marrow nucleated cells are incubated, a linear 
relationship is observed between the extracellular concentration of DNR and the 
resulting intracellular drug concentration (p < 0.001) (Fig.1). 
However, the uptake of DNR in BNML cells is less when they are incubated with 
comparable extracellular concentrations. The loss of DNR from the cells during the 
incubation and the washing procedure was always less than 5% if the cells were 
kept at 4 ·c in the dark for no longer than 1 h before they were injected into the 
animals. The viability of DNR incubated nucleated bone marrow cells and BNML 
leukemia cells immediately after the incubation procedure depended strictly on the 
extracellular drug concentration. At all concentrations used (0.2-1.0 mg/ml), less 
than 30% dead cells were observed, except at the highest concentration (52%), as 
determined by trypan blue exclusion. 
Following IV injection of the same number of nucleated bone marrow cells incubated 
with different concentrations of DNR, the in vivo recovery of DNR was tested by 
determining the drug concentration in the spleen at +1 h after drug administration 
(Fig. 2). A linear correlation can be observed between the administered drug amount 
and the spleen tissue concentration of DNR (p < 0.001). 
In subsequent experiments nucleated bone marrow cells containing DNR at different 
concentrations were injected IV into normal BN rats. The total amounts of 
administered DNR entrapped in these cells were 125, 275 and 425 jlg, respectively. 
Following this way of administration, the disposition of DNR was determined in 
bone marrow, liver, spleen, heart and plasma. In plasma no DNR at concentrations 
above the detection limit (10 ng/ml) is present at any time. The organ concentrations 
of DNR depend on the administered dose. (Fig. 3). Considerable quantitative 
differences are observed between these organs, i.e. the concentration in the spleen is 
at least 5-fold the concentration in other tissues at the same time. In Table 1 the 
tissue area under the curves from zero to +4 h are given. The main finding is that 
with cellular DNR a considerably lower AUC is achieved in heart tissue, compared 
with higher AUCs in spleen and liver. In bone marrow no difference is observed. 
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Fig. 2: 
In vivo concentrations of DNR in 
spleen tissue of BN rats following IV 
administration of different dosages 
of the drug entrapped in 5 X I 07 
nucleated bone marrow cells 
The concentrations are expressed as 
nanogram per gram of wet tissue. The 
Spearman correlation was 0.89. 
We also investigated how far leukemic cells are capable of transporting DNR to the 
leukemia-infiltrated tissues. For this purpose BNML leukemic cells were obtained 
from the spleen of terminal leukemic rats and incubated with various concentrations 
of DNR. The final intracellular amounts of DNR were 75, 175 and 250 J,J.g per 5 x 107 
cells. After IV administration of these cells the disposition of DNR is different in each 
organ studied, with the highest concentrations attained in liver and spleen (Fig. 4). 
Finally, the distribution of DNR entrapped in cells was compared with IV bolus 
injection, both after a dose of 200 jlg per animal (approx. 1.0 mg/kg). 
In normal rats, DNR administered as an IV bolus injection reaches a concentration in 
the heart which is significantly higher than when the drug is given entrapped in 
cells (p < 0.001) (Fig. 5). The amount of DOL in heart tissue with either way of 
administration is proportional to the concentration of parent drug. The DNR 
concentration attained in the spleen and the liver is higher following administration 
of the drug entrapped in cells than after IV bolus (spleen: p < 0.05; liver: p < 0.05). 
In bone marrow no significant difference is observed, except at +4 h, when the 
concentrations are significantly higher following the IV bolus gift. 
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Fig. 3: 
In vivo concentration 
of DNR in heart, bone 
marrow, liver and 
spleen in the normal 
BN rat following IV 
administration of 
5 X I 07 nucleated bone 
marrow cells with a 
final intracellular DNR 
content of 115 jlg 
(1111-11), 275 jlg (0-0) 
and 425 jlg (~-~). 
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Fig. 4: 
In vivo concentration 
of DNR in heart, bone 
marrow, liver and 
spleen in the BNML rat 
following IV 
administration of 
5 x I 07 BNML leukemia 
cells with a final 
intracellular DNR 
content of 75 ~g 
<•-•>. 175 ~g (0-0) 
and 250 ~g (~-~). 
In BNML leukemic rats a similar difference is observed between the two ways of 
administration (Fig. 6). DNR entrapped in BNML cells leads to lower concentrations 
in the heart than with IV bolus administration (p < 0.05). In spleen and liver the 
opposite phenomena is observed. Here at all time points the concentrations of DNR 
are significantly higher when the drug is administered in cells compared with IV 
administration (spleen: p < 0.05; liver: p < 0.05). In bone marrow again no difference 
is observed. 
Table 1: 
Area under the curve (0-4 h) of daunorubicin in tissues of the non-leukemic 
rat (BN)a 
AUC of DNR in tissue (mean ± SD) 
Dose of DNR Heart (~g.h/g) Spleen (~g.h/g) Liver (~g.h/g) Bone marrow 
(~g.h/1 09 cells) 
125 ~g/5.1 07 cells 2.89 ± 0.36 26.13 ± 2.21 6.32 ± 0.58 2.45 ± 0.63 
275 ~g/5.1 07 cells 5.59 ± 0.44 50.67 ± 2.48 14.96 ± 0.90 5.46 ± 0.54 
425 ~g/5.1 07 cells 7.56 ± 0.81 75.12 ± 8.17 17.75 ± 4.34 6.10 ± 0.64 
200 ~g/5.1 07 cells 4.11 ± 0.68 38.26 ± 4.86 9.82 ± 1.60 3.61 ± 0.80 
200 ~g IV 8.50 ± 0.39 18.85 ± 1.55 6.84 ± 0.46 5.02 ± 1.23 
a: Abbreviations: DNR: daunorubicin; AUC: area under the curve in tissue; BN: brown 
Norway rat 
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Fig. 5: 
In vivo concentration 
of DNR and DOL in 
heart, bone marrow, 
liver and spleen in the 
BN rat following a 
bolus Injection of 
200 J.Lg DNR {DNR: 
A-A; DOL: A-A) or IV 
administration of 
200 J.l.g of DNR 
entrapped in 5 x 107 
nucleated bone 
marrow cells {DNR: 
8-8; DOL: 0-0) 
{mean± SD) 
These findings are summarized in Table 2, using the tissue AUC as calculated from 
the observed concentrations at each dosage and/or way of administration. 
Discussion 
The pharmacokinetics of daunorubicin are characterized by a short initial plasma 
half-life, rapid accumulation of the drug in tissues and a long elimination phase 
(4,5). The in vivo cellular levels of DNR and DOL in AML patients are quite variable, 
and they cannot be predicted from plasma concentrations of DNR and DOL (2,4). 
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Table 2: 
Area under the curve {0-4 h) of daunorubicin in tissues of the leukemic rat 
{BNML)a 
AUC of DNR in tissue (mean ±SO) 
Dose of DNR Heart (J.Lg.h/g) Spleen (J.Lg.h/g) Liver (J.Lg.h/g) Bone marrow 
(J.Lg.h/1 09 cells) 
75 J.Lg/5.1 o7 cells 5.22 ± 0.11 14.96 ± 1.61 8.94 ± 1.52 1.96 ± 0.51 
175 J.Lg/5.1 07 cells 8.09 ± 0.78 14.78 ± 1.28 15.52 ± 1.80 2.53 ± 0.80 
250 J.Lg/5.1 o7 cells 9.99 ± 0.69 22.25 ± 4.71 21.54 ± 3.03 4.19 ± 1.85 
200 J.Lg/5.1 o7 cells 9.91 ± 1.92 23.27 ± 9.38 19.43 ± 3.81 3.58 ± I. II 
200 J.Lg IV 11.13 ± 2.76 10.02 ± 0.92 12.00 ± 1.44 3.44 ± 1.26 
a: Abbreviations: DNR: daunorubicin; AUC: area under the curve in tissue; BNML: brown 
Norway myeloid leukemia 
Following IV bolus injection of DNR, a rapid fall of plasma levels is associated with 
increasing levels of DNR and DOL in leukemic cells, which are capable of acquiring 
DOL by cellular uptake as well as by intracellular conversion of DNR (3,4,14). DOL 
by itself possesses considerable antitumor activity, although the relative activity 
towards leukemia as compared to DNR has not been thoroughly investigated. From 
these arguments, it is clear that pharmacokinetic analysis of DNR plasma 
concentrations only is probably not adequate for the interpretation of its 
anti-leukemic effect. However, because of the complicated pharmacokinetic picture, 
it is difficult to assess the role of intracellular DNR as regards the distribution 
kinetics of DNR and DOL. 
In previous reports we have approached the study of DNR pharmacokinetics in the 
rat (7-9), and we have demonstrated specific accumulation of DNR and to a lesser 
extent of DOL in spleen, liver and bone marrow. However, the net amount of DNR 
and DOL attained in these organs was shown to depend on the tumor load in 
leukemic animals (9). It can be appreciated that differences of the transport of DNR/ 
DOL carried by leukemic cells and/or normal white cells are responsible for the 
observed differences. 
In case of acute myelocytic leukemia it has been suggested that proliferating 
leukemic cells can return from the blood to the spleen and the bone marrow (15,16) 
and that they can be released into the circulation again (17). The permeability of the 
capillaries in these organs is a major reason for the infiltration of leukemic cells 
during the development of the disease (18). Thus, one might expect that DNR-
containing leukemic cells return to and settle in the liver, the bone marrow and 
possibly the spleen. Because of the observed accumulation of DNR in white cells in 
peripheral blood following IV administration (5), we decided to investigate to what 
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extent DNR-containing cells contribute to effective concentrations of DNR and DOL 
in these organs after IV administration. The study was performed with DNR-loaded 
nucleated bone marrow cells infused in normal rats as well as with DNR-loaded 
leukemic cells infused in leukemic rats. From Fig. 1 it is clear that exposure of BN 
normal rat bone marrow to DNR results in dose-dependent intracellular uptake of 
the drug. By incubating the cells with high drug concentrations, up to 400 )lg of DNR 
is contained in 2 x 107 cells. Following administration of these cells into the rat the 
concentrations of DNR attained in liver and spleen are larger than with a regular IV 
administration of the same dose, while in bone marrow the concentrations are 
comparable with both ways of administration. 
After administration of DNR-carrying cells, no detectable drug concentrations were 
present in the plasma of any sample. However, it is not known whether the efflux of 
drug from the cells during circulatory transport was minor. It is also possible that 
low but substantial levels of DNR in plasma were rapidly eliminated. Administration 
of DNR-loaded cells results in lower cardiac levels of this drug when compared with 
IV bolus administration, suggesting that intracellular DNR does not have a major role 
with respect to cardiotoxicity. A major difference with IV bolus is the selective 
accumulation of the drug in liver and spleen. T-9-ese data indicate that DNR present 
in cells is preferentially distributed to hemopoietic tissues. It is, however, more 
relevant to investigate this phenomena in leukemic rats, because the kinetics of IV 
DNR are significantly different between normal and leukemic rats (9). 
The distribution kinetics of leukemia cells in the BNML acute leukemia in the rat 
have been thoroughly investigated by Hagenbeek and Martens (10). When untreated 
BNML cells are infused into leukemic animals at a mature stage of the disease, 42% 
of the cells lodge in the liver, 8% in the spleen and 50% in the bone marrow. It was 
demonstrated that the majority(± 99%) of the leukemic cells are present in these 
slowly exchangeable tissues. 
The present study shows that the distribution of DNR/DOL contained in BNML 
leukemia cells does not exactly follow this pattern. Taking into account a mean liver 
weight of 8.5 g, a mean spleen weight of 2 g and a mean femoral cellularity of 
0.33 x 108 cells (representing 1.2% of the total bone marrow) the recovery of DNR 
from these organs at +4 h after IV administration of BNML cells loaded with 200 )lg 
DNR, is 16.6 )lg in the spleen (8.3%), 38 )lg in the liver (19%) and 1.8 )lg in the bone 
marrow (0.89%). 
Thus, the uptake of DNR in the spleen is exactly as can be expected from the 
distribution kinetics of leukemic cellS, but in liver and especially in bone marrow 
substantially less uptake of DNR is observed. This discrepancy may be due to a 
partial loss of the homing characteristics of the BNML cells as a result of the high 
(intra)cellular drug concentration. 
The concentrations attained in bone marrow are of the same order as after IV bolus 
administration of the same dose. In liver and in spleen, significantly larger organ 
concentrations are observed. It remains therefore to be determined to what extent 
DNR is released in vivo from the infused cells once they have arrived in tissues and 
whether the drug is subsequently taken up by adjacent leukemia cells and/or normal 
tissue. We could not demonstrate any loss of DNR from the cells during circulatory 
transport, as judged from the lack of detectable plasma concentrations. In vitro 
incubation of DNR-containing cells at 37 ·c, however, leads to leakage of DNR from 
the cells (6). 
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From the present study we conclude that DNR contained in leukemia leads to 
significantly higher levels in spleen and liver, but not in heart and in bone marrow 
when compared to IV bolus DNR. In view of the reported large levels of DNR in 
peripheral white cells of AML patients after IV administration, these data may 
indicate that DNR contained in leukemic cells may add significantly to establishing 
high tissues levels. Although these findings have no direct therapeutic implications, 
they may add to our understanding of the complicated association between the DNR 
concentration and its antileukemic effect. 
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CHAPTER 5 
Cellular pharmacokinetics of 
daunorubicin: relationships with the 
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Abstract 
In an attempt to identify pharmacokinetic factors that determine the response of 
acute myeloid leukemia (AML) patients to induction chemotherapy, we determined 
the concentrations of daunorubicin (DNR) and the main metabolite daunorubicinol 
(DOL) in vivo and particularly evaluated the concentrations in blood and bone 
marrow nucleated cells. Cell measurements were obtained in 37 evaluable patients 
during their first remission induction treatment with DNR and cytarabine (ara-C) 
and directly compared with the plasma distribution kinetics of DNR. We show that 
1) plasma DNR concentrations do not correlate with DNR concentrations in bone 
marrow nucleated cells; but 
2) plasma area under the curve (AUC) values of DNR correlate inversely (p < 0.01) 
with AUC values of DNR in white blood cells (WBC); 
3) concentrations of DNR in WBC correlate positively (p < 0.01) with DNR 
concentrations in bone marrow nucleated cells; and 
4) the concentrations of DNR in WBC show a negative correlation (p < 0.01) with the 
numbers of peripheral blast cells at diagnosis. 
We then tested whether the pharmacokinetic parameters had predictive value for the 
clinical outcome of therapy, but none of the plasma levels or WBC and bone marrow 
concentrations of DNR predicted treatment outcome. The inverse correlaton between 
the concentrations of DNR in WBC and the numbers of peripheral blast cells suggests 
that the effective DNR concentrations achieved intracellularly are mainly a function 
of the tumor load so that lesser amounts of DNR accumulate intracellularly when the 
AML cell numbers in blood are higher. 
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Introduction 
Daunorubicin (DNR) is a major drug in the treatment of acute myeloid leukemia 
(AML). Therapy with DNR in combination with cytarabine (ara-C) is commonly used 
for induction of complete remission (CR) in AML (1,2). Although the CR rate is high 
(3), 20% to 40% of patients with AML do not enter CR upon treatment with 
schedules of DNR and ara-C. Patients not attaining CR are either those individuals 
whose leukemia is resistant to the therapy or those with early death during 
remission induction (RI) therapy (4). Further improvements in the CR rate depend 
mainly on the development of more effective or less toxic agents and 
individualization of RI therapy. 
Monitoring the pharmacokinetics of antineoplastic drugs may show interindividual 
variations between patients. In recent years, studies have been performed to identify 
pharmacologic variables that determine the response of AML patients to 
chemotherapy consisting of ara-C and an anthracycline. At present, studies 
conceming cellular cytidine kinase and deaminase have failed to predict clinical 
outcome (5), as have studies of cellular ability to form activated ara-C (ara-CTP) 
(6-8). However, the ability of blast cells to retain intracellular ara-CTP following in 
vitro exposure to ara-C has been reported to correlate with remission duration in 
those patients who subsequently achieved a CR (7,9). More recently, the cellular 
pharmacokinetic studies of Plunkett et al suggest that retention of ara-CTP may be a 
determinant of therapy response. However, these relationships have been established 
for treatment with high-dose ara-C, not for conventional dosages of the drug (10,11). 
In case of Adriamycin (doxorubicin (DOX); Adria Laboraties, Columbus, OH), plasma 
levels do not correlate with the clinical response to the drug in patients with AML 
(12). DNR, like DOX, exerts its cytotoxic effect mainly through intercalation into 
DNA (13,14), and the nuclei of AML cells are the principal targets of DNR therapy. 
Therefore, determinations of cellular DNR and its pharmacologically active 
metabolite daunorubicinol (DOL), rather than the plasma parameters, would be 
expected to give prognostic information with regard to treatment response (15,16). 
Moreover, the results from a recent study have indicated that the number of tumor 
cells (tumor load) play a significant role, as far as the distribution of anthracyclines 
in tissues is concemed (17). The objective of the investigations presented here was to 
determine the in vivo cellular DNR concentrations in blood and bone marrow in 
patients during RI treatment, and to compare these with the simultaneously observed 
plasma distribution kinetics of this drug. In addition, the possible effect of the tumor 
load on the pharmacokinetic parameters of DNR was studied. We also examined 
whether the in vivo cellular DNR concentrations had predictive value for the clinical 
outcome of therapy. 
Materials and methods 
Patients 
Forty patients with previously untreated AML were enrolled in this study. The 
French-American-British (FAB) classification system was used to diagnose AML 
(18,19). Patients were treated according to the AML-6 protocol of the European 
Organization for Research and Treatment of Cancer (EORTC). After October 1983, 
elderly patients (i.e., > 65 years) with AML were treated according to the EORTC 
AML-7 protocol, and after April1986, according to the newly activated AML-9 
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protocol. RI chemotherapy contained DNR, 45 mg/m2 (AML-6 protocol) or 30 mg/m2 
(AML-7 and AML-9 protocol) on days 1, 2, and 3 by intravenous (IV) bolus; and 
ara-C, 200 mg/m2 (AML-6 and AML-7 protocol) or 100 mg/m2 (AML-9 protocol) IV on 
days 1 through 7. Protocol AML-6 also included vincristine, 1 mg/m2 IV on day 2. 
The criteria for evaluating response were those established by the Cancer and Acute 
Leukemia Group B (20). A CR was defined as a reduction in the percentage of AML 
blast cells to< 5.0%, in association with a recovery of hematopoiesis and peripheral 
blood counts to normal for at least 4 weeks. Partial remission (PR) was defined by a 
decrease in the percentage of AML blast cell infiltrate of the bone marrow to 5.1% to 
25.0%. When two courses of RI therapy had been applied and no CR reached, the 
outcome of therapy was considered as failure. The spectrum of failures of the 
induction treatment was classified according to Preisler (21): type 1, absolute drug 
resistance; type 2, relative drug resistance; type 3, regeneration failure; type 4, 
hypoplastic death; type 5, early death; and type 6, extramedullary leukemic 
persistance. 
Collection and isolation of plasma, WBC, and bone marrow from AML patients 
The optimal conditions for the collection of white blood cells (WBC), bone marrow 
nucleated cells and plasma, as well as the methodology of drug analysis, have been 
described in detail (22). In brief, blood samples (10 ml) were drawn into tubes with 
EDTA as anticoagulant, immediately before (zero minutes), and at +5, +10, +20 and, 
+30 min as well as at +1, +2, +4, +6, +8 and +24 h after the first dose of DNR during 
the first cycle of RI treatment. The samples were cooled to 4 'C and the cells were 
counted. After centrifugation, the plasma was collected and frozen, and the huffy 
coat was obtained. The huffy coat was depleted of erythrocytes by cold hypotonic 
lysis (22) and the WBC were resuspended in phosphate-buffered saline (PBS), 
counted, and also frozen. Complete plasma and WBC data were successfully obtained 
in 35 and 33 cases, respectively. 
Bone marrow cells were collected from the patients at two time points, ie, at +1 h 
(n = 31 patients) and at +24 h (n = 26 patients) after DNR treatment. Bone marrow 
(2 to 10 ml) was aspirated from the posterior iliac crest under local anesthesia into a 
syringe and immediately put into tubes containing EDTA for anticoagulation. The 
samples were cooled to 4 'C and the cells were counted. The quality of the bone 
marrow aspirates was assessed by calculating the admixture of peripheral nucleated 
cells in the samples according to Hodrinet et al. (23). After the erythroid cells had 
been lysed by exposure to hypotonic N}4Cl at 4 ·c, the nucleated cells were counted 
and then stored at -20 ·c until further processing by high-performance liquid 
chromatograpy (HPLC). All patients had given informed consent to donate blood and 
bone marrow. 
Analysis of plasma and intracellular DNR and DOL contents by HPLC 
Concentrations of DNR and DOL were determined using HPCL drug analysis as 
described previously (17,22,24). Briefly, 0.5 ml of a thawed plasma sample was 
vortexed with 0.2 ml borate buffer and 2 ml chloroform: methanol (4:1) in a 
siliconized tube. After centrifugation at 1000 x g for 10 min, 1 ml of the organic 
phase was evaporated to dryness under nitrogen at 35 ·c. 
To avoid heterogeneous drug recoveries from patient samples with different cell 
concentrations, we standardized the WBC and bone marrow samples with PBS at 
final concentrations between 109 to 10 x 109 cells/l before entering the extraction 
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procedure. Borate buffer (0.2 ml) and 5 ml chloroform: methanol (4:1) were added to 
2 ml of the cell suspension and shaken for 20 min. After centrifugation, 1 ml of the 
organic phase was dried under nitrogen. 
Dried samples were reconstituted in 300 ~chloroform: methanol (4:1) and 100 ~ 
aliquots were then injected onto an HPLC column containing 7 11m silicagel particles 
(Lichrosorb Si-60-7; Chrompack, Middelburg, The Netherlands). The mobile phase 
consisted of chloroform, methanol, acetic acid, water, and 3 mmol/1 MgCh solution 
in water (720:210:40:24:6 by volume); the flow rate was 1.3 ml/min. Detection of 
anthracycline was accomplished with a fluorometer (Gilson Spectra-Glo; Meyvis en 
Co BV, Bergen op Zoom, The Netherlands) using excitation at 480 nm and emission 
at 550 nm. Retention times and areas of the peaks were recorded by a Shimadzu 
Model CR3A integrator (Chrompack Packard BV, Delft The Netherlands). 
Concentrations of DNR and DOL were quantified by using doxorubicin as an internal 
standard. The lower detection limit of DNR was 5 ng/ml plasma and 21J.g/109 
nucleated cells. 
Pharmacokinetic analysis 
The data from the 40 AML patients were analyzed by fitting a two-compartment 
open model to the observed plasma DNR concentrations (25,26). The plasma 
concentration-time curve following IV bolus injection of DNR was described by the 
following equation: 
C(t) = A.e-a.t + B.e-~.t (1) 
where C(t) is the plasma level of DNR at each time (t) after injection, A and B are 
constants, and a and ~ are first-order decay rate constants. The plasma area under 
the concentration-time curve (AUC), the apparent distribution volume (Vdarea) and 
the elimination rate constant (kel) were calculated from this model. The plasma 
clearance (Cl) during 24 h following drug administration was derived from: 
dose 
Cl= AUC 0-24h (2) 
The plasma AUC of DOL and the intracellular AUC of DNR were determined by the 
trapezoidal method (27). 
Statistics 
The Spearman test was used for calculating correlation coefficients and the 
Wilcoxon test was used for comparison of groups (28,29). 
Results 
Clinical data 
During the study period, 40 new patients with AML were entered of whom 3 (75, 69, 
and 67 years) died within the first week following completion of therapy or during 
the hypoplastic phase (failures type 4 or 5). Table 1 lists the clinical and treatment 
characteristics of the remaining 37 AML patients who could be evaluated for 
response. 
The results of RI therapy were as follows: CR, 20 of 37 (54%); PR, ten of 37 (27%); 
and resistant disease (RD) (failure type 1), seven of 37 (19%). The group of aged AML 
patients among these received a somewhat lower dose of DNR (30 mg/m2); the 
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outcome of RI therapy of those seven evaluable elderly patients was not different 
(CR, five of seven; RD, two of seven). 
WBC counts (range, 0.417 to 239 x 109 cells/1), percentages of peripheral blast cells 
(range, 1% to 100%), and absolute numbers of peripheral blast cells (range, 0.009 to 
210 x 109 cells/1) at diagnosis showed significant interindividual variations (Table 1). 
Pharmacokinetic parameters of DNR in plasma, WBC, and bone marrow 
The pharmacokinetics of DNR were studied in all patients during the frrst remission 
induction therapy. The plasma concentrations of DNR fell to minimal levels at +8 h 
after IV injection (Fig. 1). The rapid decline was associated with a fast appearance of 
the major metabolite DOL in the plasma. Generally, DOL plasma concentrations 
exceeded DNR plasma levels as early as at +0.5 h to +1 h after administration and at 
+4 h the DOL concentrations accounted for> 85% of the total amount of measurable 
anthracycline. With our method of analysis no metabolites other than DOL were 
found. 
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Table 1: 
Patient characteristics 
Patient Sex Age FAB WBc?- Blastil Blasts Blastil Dose Dose Numb- Out-
classi- (x 109/1) in inll in of of erof come 
fic<rtion peri ph- peri ph- bone DNR DNR RI ofRI 
eral eral marrow (mg/m~ (mg) courses therapy 
blood blood (%) 
(%) (x 109/1) 
I M 32 Ml 3.2 90 288 90 45 100 I CR 
2 M 74 M4 3.8 I 0.04 68 30 60 I CR 
3d M 73 Ml 13.0 70 9.10 49 45 80 I CR 
4 M 40 M2 17.6 61 10.7 84 45 75 I CR 
5 F 56 M2 33 5 0.17 36 45 75 I CR 
6d M 23 M2 15.0 39 5.85 57 45 80 I CR 
7 M 58 M2 D.417 I 0.004 32 45 90 I CR 
8f F 67 MS 0.590 10 0.06 94 30 50 I CR 
9 F 34 M2 1.493 34 0.51 86 45 70 2 CR 
10 M 60 M4 40.1 26 10.4 74 45 90 2b CR 
II M 62 M2 1.545 I 0.02 53 45 80 2b CR 
12 M 39 Ml 0.9 I 0.009 62 45 85 2b CR 
13 F 65 Ml 0.937 I 0.009 83 45 70 2 CR 
14 M 56 M4 1.736 4 0.07 70 45 85 2b CR 
IS F 62 MS 13.4 6 0.80 80 45 90 2b CR 
16 M 58 Ml 20.0 62 124 85 45 75 2 CR 
17 M 37 Ml 0.7 I 0.007 93 45 100 2 CR 
18f M 61 Ml 140.4 94 132 85 30 55 2 CR 
19f F 66 M2 0.538 2 0.01 47 30 45 2 CR 
20f F 64 M2 0.799 6 0.05 80 30 50 2 CR 
21c+e M 66 MS 48.5 66 320 73 45 70 I PR 
22e M 47 M4 102 83 84.7 67 45 90 I PR 
23e M 56 Ml ISO 100 ISO 96 45 80 I PR 
24 M 42 Ml 1.44 18 0.26 66 45 75 2 PR 
25 M 47 M4 5.0 65 3.25 85 45 90 2 PR 
26 M 37 M4 liS 76 87.4 81 45 90 2 PR 
27 M 26 M4 239 88 210 86 45 80 2b PR 
28 M 33 MS 17.6 41 7.22 94 45 80 2b PR 
29 M 46 MS 45.0 40 18.0 64 45 80 2 PR 
30 M 43 MS 60.0 20 120 77 45 95 2 PR 
31d M 70 Ml 58.5 95 55.6 97 45 80 I Failure type I 
32 M 44 M4 20 5 0.10 78 45 95 I Failure type I 
33 M 70 M4 33.0 1.5 0.50 43 30 60 I Failure type I 
34 F 73 M4 132 22 0.29 70 30 50 I Failure type I 
35d F 42 M4 4.2 8 034 33 45 80 I Failure type I 
36 M 17 M2 6.5 79 5.14 70 45 80 2 Failure type I 
37c M 66 MS 16.4 36 5.90 84 45 80 2 Failure type I 
a) At diagnosis (before therapy). 
b) Patients who were not only analyzed for DNR pharmacokinetics during the first but also during 
the second course of Rl therapy. 
c) Patients (> 65 years) who were treated according to the AML-6 protocol of the EORTC, before 
the AML-7 protocol for elderly patients was activated (October 1983). 
d) Protocol variations: patients who were classified as having an antecedent hematologic disorder 
and who were not treated according to the AML-6, AML-7 or AML-9 protocols, but who received 
lower amounts 'if DNR: patients no. 6 and 35: DNR. 45 mg/m2 days I, 2; patients no. 3 and 31: 
DNR. 45 mg/m day I. 
e) Patients who achieved PR after one course of Rl therapy, but who did not receive a second 
course of Rl therapy, because of patient refusal of further chemotherapy (patient no. 21) or 
death from pneumonia (patients no. 22 and 23). 
f) Patients (> 60 years) who were treated according to the AML-9 protocol for elderly patients, 
activated April 1986. 
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DNR accumulated heavily in the WBC. Assuming that 109 cells represent a volume of 
about 1 ml, we determined the ratio of WBC to plasma concentration of DNR in the 
blood. This WBC to plasma DNR ratio increased from 55 at +5 min, to 200 at +1 h, 
and subsequently towards 470 at +4 h after IV injection. In all patients, maximum 
WBC concentratons of DNR were reached almost immediately upon administration of 
the drug. At +24 h, the cellular DNR concentrations had decreased to low levels in all 
37 patients. In 18 of 37 patients, no DOL metabolite was detectable in the WBC. In 
the other patients (19 of 37), the WBC concentrations of DOL ranged from 3% (at 
+5 min) to 15% (at +4 h) of the total amount of measurable anthracycline, and at 
+24 h the WBC concentrations of DOL had decreased to low or undetectable levels 
(data not shown). 
The DNR concentrations in the bone marrow nucleated cells at +1 has well as at 
+24 h showed great variations among the patients (range, 0 to 27 nmol/109 nucleated 
bone marrow cells (+1 h); 0 to 13 nmol/10 9 nucleated bone marrow cells (+24 h)). The 
+24-hour bone marrow DNR concentrations were always lower than the comparative 
+1-hour values (Fig. 2). As for the WBC determinations, the DOL concentrations in 
bone marrow nucleated cells (+1 h, +24 h) were low, as compared with DNR, and 
accounted for 6% and 40% of the total amount of measurable anthracycline, 
respectively. 
Twenty-one patients received identical chemotherapy in a second effort to attain CR. 
Seven of these patients were studied again during this repeat course of RI therapy. 
Keeping in mind the considerable interindividual differences in the DNR 
concentrations in the bone marrow, we compared the uptake of DNR in the bone 
marrow nucleated cells (at +1 h) for those seven patients during the two successive 
chemotherapy cycles. It appeared that the DNR values in bone marrow cells were 
equivalent during both chemotherapy cycles (Fig. 3). 
The plasma concentration-time curves of DNR could be described by equation 1, 
with a goodness of fit> 0.99 in all cases. Table 2 shows the calculated plasma 
pharmacokinetic parameters of DNR, the calculated plasma AUC at zero to 24 h of 
DOL, and the calculated WBC AUC at zero to 24 h of DNR. A wide interindividual 
range of all parameters is apparent from these data. No correlation appeared 
between the age of the patients and the plasma clearance derived from equation 2. 
63 
Table 2: 
Pharmacokinetic parameters 
Patient tl/2a tl/2~ kei Vdareaa Plasma Plasma Plasma WBC 
(min) (min) W') (I) clearance DNR DOLb DNRb 
(1/h) AUC AUC AUC 
0-24 h 0-24 h 0-24 h 
(nmol.h/ (nmol.h/ (nmol.h/ 
ml) ml) I 09 cells) 
I 1.16 45 14.28 452 416 0.46 5.88 128 
2 1.73 52 6.92 466 374 0.31 6.28 148 
3 1.24 85 14.63 247 121 1.26 5.79 93 
4 1.06 22 12.06 443 847 0.17 5.92 164 
5 5.67 116 1.51 595 213 0.67 5.10 370 
6 1.10 32 22.68 176 230 0.66 4.10 206 
7 2.71 123 1.52 1318 447 0.38 2.33 396 
8 4.70 113 1.03 632 232 0.41 3.08 68 
9 4.50 717 1.11 1636 95 1.09 8.51 9 
10 2.52 113 5.58 504 186 0.92 19.03 34 
II 0.75 31 44.48 154 204 0.74 2.49 19 
12 0.97 22 5.64 730 1353 0.12 2.56 ND 
13 4.04 130 1.61 639 204 0.65 1.01 ND 
14 3.19 76 3.22 400 220 0.73 4.00 380 
15 1.80 74 5.60 844 473 0.36 2.27 449 
16 2.34 48 3.64 474 411 0.35 5.91 138 
17 1.94 100 5.08 949 393 0.48 2.17 84 
18 NDc ND ND ND ND ND ND ND 
19 ND ND ND ND ND ND ND ND 
20 2.20 118 3.74 710 251 0.38 1.55 62 
21 1.19 36 15.76 341 394 0.34 0.89 29 
22 1.19 128 8.49 631 204 0.83 36.29 28 
23 1.89 52 6.94 974 782 0.19 3.36 549 
24 1.16 78 13.02 403 214 0.67 2.54 4 
25 1.15 33 15.78 202 256 0.67 2.69 151 
26 6.10 185 0.77 1180 266 0.64 6.77 333 
27 1.18 123 9.93 546 184 0.82 2.97 309 
28 8.44 217 0.91 1347 258 0.58 2.35 300 
29 2.52 79 3.96 898 475 0.32 1.26 152 
30 6.05 87 1.31 1246 598 0.30 3.49 241 
31 1.07 14 15.88 224 650 0.23 3.96 86 
32 1.15 18 21.79 217 494 0.36 3.01 63 
33 1.21 26 9.61 429 685 0.17 4.89 96 
34 7.37 67 1.40 801 496 0.19 2.01 629 
35 4.55 92 1.33 734 331 0.46 15.52 71 
36 6.19 138 0.87 864 260 0.58 2.64 36 
37 6.41 113 1.48 940 346 0.44 2.02 396 
a) Apparent distribution volume. 
b) The AUC was determined by the trapezoidal method. 
c) ND, not done (blood sampling or isolation of WBC was not possible at all time points). 
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Interrelations between cellular and plasma pharmacokinetic parameters 
The plasma pharmacokinetic parameters of DNR were compared with those in WBC. 
It appeared that the concentrations of DNR in plasma (at any of the time points) did 
not correlate with DNR concentratios in WBC. However, the integrals of the 
concentrations (C) of DNR in plasma over t, where C x t indicates AUC, showed 
negative relationships with AUC values of DNR in WBC. This suggests that C x t may 
be an important parameter in describing the pharmacokinetics of DNR. The plasma 
AUC values (zero to 30 min and zero to 60 min) of DNR were inversely correlated 
with the WBC AUC values at zero to +4 h, and with the WBC AUC values at zero to 
+24 h of DNR. An example of the inverse relationship between the plasma AUC of 
DNR and the WBC AUC of DNR is shown in Fig. 4. In accordance with the WBC data, 
the bone marrow concentrations of DNR (+1 h, +24 h) did not show any correlation 
with the plasma DNR concentrations either. However, AUC values of DNR in bone 
marrow nucleated cells could not be determined. 
Concerning the interrelations between DNR concentrations in nucleated cells derived 
from blood (WBC} and bone marrow, a positive correlation between the DNR 
concentrations in WBC and the DNR concentrations in bone marrow nucleated cells 
was apparent at +1 h (p < 0.02, Fig. 5). 
Correlations of pharmacokinetic parameters and tumor load 
The DNR levels attained in WBC shortly after administration of the drug showed 
inverse correlations with the peripheral blast cell numbers at diagnosis. As an 
example, the inverse relationship between DNR levels in WBC at +10 min and the 
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numbers of peripheral blasts (at diagnosis) is shown in Fig. 6 (p < 0.01). Thus, the 
uptake of DNR by WBC was significantly reduced when blast cell numbers in the 
blood were high. 
The percentages of blast cells in the pretreatment bone marrow did not correlate 
with any of the pharmacokineti;:: parameters determined. Absolute blast cell 
numbers in the pretreatment bone marrow were not determined. 
Correlations of pharmacokinetic parameters and response to therapy 
The relevance of pharmacokinetics of DNR in relation to the outcome of treatment 
was investigated by comparing the above-mentioned pharmacokinetic parameters 
among the three response categories of patients, ie, CR, PR, or RD patients. 
The amount of DNR present in WBC at any time after administration (illustrated as 
an example for the +10-minute values in Fig. 7A) had no predictive value for the 
clinical response to therapy. A lack of relationship was also apparent between the 
DNR levels in bone marrow nucleated cells at +1 hand at +24 h (Fig.7B) and 
therapeutic response. Neither did any of the plasma DNR levels (determined day 1) 
predict for the outcome of treatment. As an example, the +4-hour plasma DNR levels 
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on day 1 are shown in Fig. 8. Although the patients having RD showed a tendency of 
lower plasma levels of DNR as compared with CR or PR patients, the differences 
were not statistically significant. 
Figure 7 and 8 also show that the patients who received the lower dose schedule of 
DNR (30 mg/m2 instead of 45 mg/m2) generally did not have reduced cellular and 
plasma DNR levels. The absence of a relationship between DNR measurements and 
DNR dosages among these patients may be explained by the high interindividual 
range of the cellular and plasma DNR levels observed in vivo. 
Neither in plasma nor in cells were the levels of the metabolite DOL associated with 
clinical response to therapy (data not shown). 
Since several patients (six of 20) underwent a bone marrow transplantation in CR, 
duration of remission could be determined in 14 nontransplant patients only. In this 
small group of patients the plasma or cellular pharmacokinetic parameters of DNR 
had no predicitive value for remission duration. 
Discussion 
The responsiveness of human AML to cytotoxic drugs is determined by many 
variables. To better understand the response of individual patients to chemotherapy, 
individual monitoring of drug levels in AML cells may be useful. Prior investigations 
that dealt with the cellular metabolism of the other active drug in AML, ara-C at 
conventional dosages, had failed to demonstrate a clear relation with the clinical 
response (5-11). Likewise, the analysis of the plasma kinetics of DOX, an 
anthracycline, in a multicenter study did not provide pharmacokinetic variables 
indicative for clinical response (12). The major goal of the present study was to 
investigate whether the in vivo cellular uptake and metabolism of DNR in the target 
tissue, ie, the bone marrow nucleated cells and WBC, had any relation with the 
clinical outcome of treatment. 
In a group of 37 patients with previously untreated AML who were evaluable for 
response, the pharmacokinetic parameters of DNR showed considerable 
interindividual variability. These differences were unlikely to be due to 
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methodological variability, rather they were indicative of patient heterogeneity. In 
seven patients in whom we were able to perform pharmacokinetic measurements 
during two successive chemotherapy cycles (within a time interval of 4 to 6 weeks), 
the DNR contents of bone marrow nucleated cells (at +1 h) were similar on the two 
occasions. Certain predetermined pharmacokinetic parameters were analyzed 
prospectively in the patients, ie, 
1) plasma kinetics of DNR, 
2) uptake of DNR in WBC at sequential time points, and 
3) levels of DNR in bone marrow nucleated cells at +1 hand +24 h after injection of 
the drug. 
The analysis also included the determination of a major metabolite of DNR, ie, DOL. 
Of 37 patients, 20 achieved CR, ten PR, and seven had RD. The older AML patients 
who received a somewhat lower dose of DNR (30 mg/m2) were also included in the 
analysis. It appeared that the response rate among these patients was comparable to 
that of younger subjects. In this study, the patients did not receive DNR as a single 
drug. They were treated with combination chemotherapy containing DNR and ara-C. 
When interpreting the experimental data from this study, we assumed that 
1) the AML cells of the refractory patients were not sensitive to DNR, and 
2) the cells of the 20 CRs were most probably sensitive to DNR (we realize that a 
limited fraction of these patients might have attained CR following treatment 
with ara-C alone (30)). 
Quantification of drug effects in AML on the basis of its plasma pharmacokinetics is 
of clinical value, in particular when plasma drug levels reflect those in target tissues. 
However, the biological features of human AML are heterogeneous. Not only the 
grade of differentiation of the cells and their clonogenic and metabolic activity, but 
also the sites of the disease in the body may vary considerably among patients. 
These differences complicate the relationships between plasma drug concentrations 
and the therapeutic effects. Measurements of the anthracycline DOX and its 
metabolite doxorubicinol in plasma at +3 h had failed to disclose different drug 
levels for therapy responsive and resistant patients (12). In our study, plasma DNR 
levels at a comparable time after administration (+4 h) did not predict for the 
outcome of RI therapy either. In addition, neither did any of the plasma DOL levels 
predict for the outcome of treatment, but it is possible that the plasma levels of 
other metabolites would give more valuable information as has been suggested for 
the DNR aglycones (31). 
It is noteworthy that plasma AUC values of DNR were inversely correlated with AUC 
values of DNR in WBC, ie, the higher the AUC values of DNR in WBC, the lower the 
plasma AUC values of DNR. This suggests that the DNR is readily absorbed from 
plasma by WBC, but that the exchange between WBC and plasma is slow. Our data 
indicate that DNR levels in WBC and bone marrow nucleated cells are comparable. 
This is in agreement with the concept of exchangeable pools of AML blast cells, 
traversing between blood and bone marrow. Therefore, it cannot be expected that 
plasma concentrations of DNR respresent the levels attained in AML blast cells in 
tissues. Monitoring of cellular DNR concentratons in blood, rather than plasma DNR 
concentrations, may yield an indication of the bone marrow concentration of DNR 
instead. In analogy with this, DeGregorio et al. (16) found that plasma 
concentrations of DNR and DOL did not correlate with the inhibition of DNA 
synthesis of myeloblasts. 
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Theoretically, the plasma pharmacokinetics of DNR and DOL may not only have 
prognostic meaning for antileukemic response, but also for predicting toxicity. 
Therefore, we also evaluated a possible relationship between plasma 
pharmacokinetics of DNR and DOL and the duration of bone marrow depression 
(expressed as the length of the nadirs [in days] of granulocytes and thrombocytes), 
but no positive relationship appeared (data not shown). This paper mainly addressed 
the issue of pharmacokinetic relevance and response. The probability to obtain CR 
was not associated with high concentrations of DNR in WBC nor in bone marrow 
nucleated cells. With respect to the cellular DNR pharmacokinetic parameters, no 
differences between the cytological subgroups of leukemia (M1, M2, M4 and M5) 
were observed. Thus, no relation was evident between the cellular DNR levels 
attained in vivo and the clinical response to therapy. On the other hand, the data 
revealed an inverse relationship between the numbers of circulating blast cells and 
the DNR levels in WBC. This suggests that the WBC concentrations of DNR attained in 
vivo are a function of the tumor load, and that lesser amounts of DNR accumulate in 
the WBC when the circulating blast cell numbers in blood are higher. Our 
observations would be in agreement with the results of the preclinical investigations 
of Nooter et al. (17), which indicated that the presence of a high leukemic cell load 
plays a role in the different pharmacokinetics of DNR in normal and leukemic rats. 
Previous studies have established that AML patients presenting with higher tumor 
loads generally have inferior responses to treatment as compared to patients 
presenting with lower tumor loads (32,33). Therefore, we hypothesize that the effect 
of the tumor burden on the cellular uptake of DNR in AML patients is a determinant 
of the clinical responsiveness to treatment. 
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CHAPTER 6 
In vivo uptake of daunorubicin by acute 
myeloid leukemia cells measured by 
flow cytometry 
This chapter (in vivo data) combined with parts of Chapter 3 (in vitro data) are 
based on investigations published in: 
Leukemia 2:511-517 
Esther Kokenberg, Pieter Sonneveld, Ruud Delwel, Willemijn Sizoo, Anton 
Hagenbeek and Bob Lowenberg 
In vivo uptake of daunorubicin by acute myeloid leukemia cells (AML) measured by 
flow cytometry. 
Abstract 
Monitoring of daunorubicin (DNR) concentrations in leukemic cells in blood and 
bone marrow in vivo of patients with acute myeloid leukemia may yield insight into 
the interindividual variations of the clinical response to treatment. DNR 
concentrations of leukemic cells in blood and bone marrow were measured with flow 
cytometry in 17 evaluable patients during their first remission induction treatment 
with DNR and cytosine arabinoside. The results indicate that: 
a) DNR fluorescence of leukemic blast cells is intermediate between the smaller 
lymphocytes and the approximately equally large granulocytes; 
b) DNR fluorescence of peripheral blast cells and bone marrow blast cells correlate 
well (p<0.001); and 
c) patients reaching complete remission show a tendency of higher DNR 
fluorescence of leukemic blast cells than do partial responders. 
Introduction 
Daunorubicin (DNR) is an anthracycline antibiotic effective in the treatment of acute 
myeloid leukemia (AML) (1-5). Differences in the responsiveness of AML to the 
cytotoxic effects of DNR among patients are not well understood, and may be related 
at least in part to differences in metabolism and distribution of the drug. The 
pharmacokinetics of anthracyclines in plasma have been studied extensively with 
high-performance liquid chromatography (HPLC) in AML patients (6-8) and have 
shown that plasma anthracycline levels do not correlate with the clinical response to 
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the drug (9,10). Since the cytotoxic effect of DNR is correlated with an interaction 
with DNA (11-13), it is likely that monitoring of the cellular DNR levels will give 
insight into the factors determining the differences in the responses. 
In a previous study, that was based on HPLC measurements, we could not establish a 
relation between the DNR levels attained in vivo in white blood cells (WBC} or bone 
marrow cells and the clinical response to therapy (10). However, using HPLC, the 
DNR concentrations were measured in total WBC or whole bone marrow nucleated 
cells only and separate measurements of DNR concentrations in subpopulations of 
cells (i.e., leukemic cells) were not carried out. In vitro studies with cell lines (14-22) 
employing animal (23) or human (leukemic) cells (24-27) and the data presented in 
Chap. 3 have shown that the fluorescent property of the anthracyclines allows for 
measuring of the cellular drug concentrations with flow cytometry. However, data 
on the anthracycline concentrations attained in vivo in human leukemic cells during 
treatment are scarce (28). 
The objective of the investigations presented here was to evaluate the applicability 
and potential usefulness of flow cytometry for measuring DNR concentrations in 
leukemic cells in peripheral blood and bone marrow in vivo. 
Materials and methods 
Patients 
Seventeen patients with previously untreated AML were enrolled in the study. The 
criteria of the French-American-British working party were used to classify the 
cytological diagnosis of AML (29,30). Chromosome banding analysis of nucleated 
bone marrow cells was performed according to standard techniques (A. Hagemeijer, 
Dept. of Cell Biology and Genetics, Erasmus University Hospital Dijkzigt, 
Rotterdam) (31). Patients were treated according to the AML-6 protocol of the 
EORTC. Elderly patients with AML (i.e., over 65 years) were treated according to the 
EORTC AML-7 protocol, and after April 1986 according to the AML-9 protocol. 
Remission induction (RI) chemotherapy included DNR, 45 mg/m2 (AML-6 protocol) or 
30 mg/m2 (AML-7 and AML-9 protocols) on days 1, 2 and 3 by intravenous (IV} bolus; 
and ara-C, 200 mg/m2 (AML-6 and AML-7 protocols) or 100 mg/m2 (AML-9 protocol) 
IV on days 1-7. Protocol AML-6 also included vincristine, 1 mg/m2 IV on day 2. The 
criteria for evaluating response were those established by the Cancer and Acute 
Leukemia Group B (32). The spectrum of failures of the induction treatment were 
classified according to Preisler (33). 
Collection and isolation of WBC and bone marrow from AML patients 
The optimal conditions for the collection of WBC and bone marrow nucleated cells, 
as well as the methodology of drug analysis by HPLC have been described in detail 
before (34). In brief, blood samples (10 ml) were drawn into tubes with EDTA 
immediately before (blank sample), at +1 h (n = 17 patients) and at +24 h (n = 14 
patients) after the first dose of DNR during the first cycle of RI treatment. The 
samples were cooled to 4 ·c, and after centrifugation (450 x g, 10 min, 4 "C) the 
plasma was removed. The huffy coat was depleted of erythrocytes by cold hypotonic 
lysis (34) and the WBC were resuspended in PBS, counted and kept at 4 ·c until flow 
cytometric analysis. Part of the WBC suspension was stored at -20 ·c until further 
processing by HPLC. 
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Bone marrow cells were collected from the patients at the same time intervals as 
well i.e., immediately before, at +1 h (n = 17 patients) and at +24 h (n = 14 patients) 
after the onset of DNR infusion. Bone marrow (2-10 ml) was aspirated from the 
posterior iliac crest under local anesthesia and put into tubes containing EDTA The 
samples were cooled to 4 ·c and after lysis of erythroid cells the nucleated cells were 
resuspended, counted and stored or used for flow cytometry. 
All patients had given informed consent to donate blood or bone marrow. 
Measurement of cellular DNR content by flow cytometry 
The DNR content of individual cells was measured with flow cytometry as described 
in Chapter 3. Briefly, cells from the cell suspension passed the 488 nm laser beam 
running at 0.4 W of a Becton-Dickinson (Mountain View, CA) fluorescence activated 
cell sorter (FACS 440). The forward and perpendicular light scatters from the cells 
were used to distinguish the different cell types in WBC or in bone marrow (35). 
Dead cells among the WBC and bone marrow populations were excluded from 
analysis by elevating the threshold of the forward light scatter. For each sample, at 
least 10 x 103 cells were analysed at a flow rate of 1-2 x 103 cells/s. 
Data analysis was performed using a Hewlett Packard 68B system. Fluorescent 
profiles were recorded as histograms of fluorescence intensity versus cell frequency. 
A representative example is shown in Fig. 1. The relative value of DNR fluorescence 
was obtained for each population by calculating the mean of the fluorescence 
distribution. Mean fluorescence was expressed in arbitrary units, taking into account 
the blank samples that were used to correct for background fluorescence 
(subtraction of blank values). 
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Table 1: 
Clinical characteristics of patients 
WBC Blasts Number 
Prognostic (x109 Blasts in Dose of of Rl courses 
Patient Age categor/ FAB II? in blood bone DNR 
Cytogenetic classif- (xl09 marrow(~ Outcome 
Sex i<ar")Qty¢ ie<rtion (%)a II) a (%)a ~ ) (mg) Rl therapy 
I F 56 NI'F I M2 33 5 0.17 36 45 75 CR 
2b M 23 AN t(8;21) F M2 15.0 39 5.85 57 45 80 CR 
3 M 58 AA+8 u M2 0.417 0 0 32 45 90 I CR 
4d F 67 AN+8 u M5 0590 10 0.06 94 30 50 I CR 
5 M 17 ANt(9;11) u M4 4.1 39 1.60 63 45 90 I CR 
6 M 56 AN-5,7q- u M4 1.736 4 0.07 77 45 85 2 CR 
7 F 62 NN MS 13.4 44 5.90 84 45 90 2 CR 
8 M 58 NN Ml 20.0 62 12.4 85 45 75 2 CR 
9 M 37 AN+4 u Ml 0.7 0 0 93 45 100 2 CR 
lod F 64 NN I M2 0.799 6 0.05 80 30 so 2 CR 
II M 33 AA 16q- u M5 17.6 54 950 94 45 80 2 PR 
12 M 46 NN I MS 45.0 40 18.0 71 45 80 2 PR 
13 M 43 AAinv(l6) F MS 60.0 70 42.0 84 45 95 2 PR 
14 M 44 AN7q- u M4 2.0 5 0.10 78 45 95 I NRg 
ISc M 70 AN hypodiploid u M4 33.0 15 050 43 30 60 I NR 
16b F 42 AA pseudodiploid u M4 4.0 73 2.92 69 45 so NR 
IJd M 68 AN+8 u M2 1.49 3 0.04 56 30 60 NR 
a: At diagnosis (before therapy). 
b: Protocol variations: patients who were suspected of having an antecedent hematologic 
disorder were treated according to the AML-6 protocol, but received DNR during two 
instead of three days. 
c: Patient (> 65 years) who was treated according to the AML-7 protocol for elderly 
patients (see: Materials and methods). 
d: Patients (> 60 years) who were treated according to the AML-9 protocol for elderly 
patients (see: Materials and methods). 
e: NN: diploid karyotype (I 00% normal cells); AN: mixture of abnormal and normal cells; 
AA: I 00% abnormal cells. 
f: F: favorable; 1: intermediate; U: unfavorable (adapted from MJ Keating et al., 1987, 
Leuk Res II, 119-133). 
g: NR: no response patients, failure type I. 
Analysis of cellular DNR and daunorubicinol by HPLC 
Concentrations of DNR and its major metabolite daunorubicinol (DOL) were 
determined using straight-phase HPLC analysis as described previously (10,34,36). To 
avoid heterogeneous drug recoveries from patient samples with different cell 
concentrations, we standardized the leukocyte and bone marrow samples with PBS 
at final concentrations between 109 to 10 x 109 cells/l before entering the extraction 
procedure. For drug quantification, doxorubicin was used as an internal standard. 
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Statistics 
The Spearman test was used for calculating correlation coefficients. 
Results 
Clincal data 
Table 1 lists the clinical and treatment characteristics of 17 patients with AML, who 
were included in the clinical study. The results of RI therapy were as follows: CR 
10/17 (59%), PR 3/17 (18%), and resistant disease (NR) (failure type 1) in 4/17 (23%). 
Four aged AML patients among these individuals received the relatively lower dose 
of DNR (30 mg/m2). The outcome of RI therapy of those 4 elderly patients was: CR 
2/4 and NR 2/4. 
The cytogenetic data have been listed in Table 1. An euploid karyotype (NN) was 
found in 5/17 patients. Eight of the 12 patients with an abnormal karyotype had a 
mozaicism of abnormal and normal cells (AN), while 4 patients had 100% abnormal 
cells (AA). The cytogenetic findings were classified in prognostic cytogenetic 
categories according to Keating et al. (37). [He analysed the influence of karyotype 
on response rate, remission duration and survival. He concluded that inv(16) and 
t(8;21) were favorable prognostic categories (more common in young patients), 
diploid, t(15;17), and 45,X,-Y had intermediate prognosis, and all other categories 
were unfavorable prognostic groups (more common in older patients)]. As indicated 
in Table 1 favorable karyotypes were found in 2/17 patients, intermediate 
karyotypes in 5/17 patients and unfavorable karyotypes in 10/17 patients. 
Correlation of the prognostic categories with response show that 4/4 patients with 
resistant disease had unfavorable karyotypes. The CR and PR patients did not show 
any correlation with the cytogenetic prognostic categories. 
Cellular DNR concentrations in vivo 
As flow cytometry does not distinguish between the parent drug (DNR) and the 
metabolite DOL but measures overall fluorescence, the patient WBC and bone 
marrow samples were also assayed with HPLC for cellular content of DNR and DOL. 
HPLC measured no demonstrable DOL metabolite in the cells in 9/17 patients. In the 
other patients the metabolite was never more than 15% (at +1 h) of the total amount 
of measurable anthracycline and at +24 h the cellular concentrations of DOL had 
decreased to minimal or undetectable levels. Therefore, the contribution of the 
metabolite DOL was not taken into consideration in the following analyses. 
The in vivo relationships between fluorescence and HPLC values correlated 
somewhat less well than those for the in vitro incubations (Chapter 3), but again a 
positive relationship was obvious between the cellular DNR concentrations in WBC 
and bone marrow nucleated cells at +1 hand at +24 has determined by HPLC versus 
flow cytometry (n =55, R = 0.5695, p < 0.001) (data not shown). The DNR fluorescent 
signals obtained from WBC and bone marrow cells at +1 h were easily detectable 
with flow cytometry. At +24 h the cellular DNR fluorescent signals had decreased to 
low levels in all patients and approached the detection limit, which was in 
concordance with the DNR concentrations derived from HPLC analysis. 
Cellular DNR concentrations in subpopulations of cells 
All the above reported measurements were done with whole WBC or bone marrow 
nucleated cells. We then investigated the DNR concentrations in subpopulations of 
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Fig.2: 
Dot display of forward light scatter 
(fLS) versus perpendicular light 
scatter (PlS) of nucleated bone 
marrow cells from a patient with 
AMI. 
The erythrocytes and normoblasts were 
lysed. Each dot represents one cell. The 
combination of FLS and PLS reveals distinct 
cell types which were identified by sorting 
the cells followed by cytospin preparation, 
staining and microscopic examination. 
cells, i.e., in particular in the blast cell fraction. Since prior treatment of a blood or 
bone marrow sample with lysis buffer had removed the erythrocytes and the 
normoblasts almost completely, the lymphocytic, myeloid and blast cell populations 
could be clearly distinguished on the basis of forward and perpendicular light 
scatter properties (34) as indicated in Fig. 2. The cell types were identified by sorting 
the cells followed by cytospin preparation, staining and microscopic examination. By 
placing windows in the forward-perpendicular light scatter plane, the mean 
fluorescence of these distinguishable subpopulations was measured. 
Separate measurements of DNR in subpopulations of cells showed a good correlation 
between DNR concentrations in peripheral blast cells and in bone marrow blast cells 
at +1 h (p < 0.001, Fig. 3). However, the blast cell DNR concentrations in the bone 
marrow were lower than the comparative values of blast cells in the blood. In 
several cases blood and bone marrow samples of the same patient contained enough 
non-leukemic cells for measurement of DNR concentrations. Good correlations were 
found between DNR concentrations in normal blood and bone marrow cell types at 
+1 h (lymphocytes: n=9, R=0.6958, p < 0.05; granulocytes: n=8, R=0.9286, p < 0.01). 
Again, the cellular DNR concentrations in the bone marrow were lower than the 
comparative values in the blood cells (data not shown). 
Flow cytometric measurements showed that different cell types expressed different 
levels of DNR-associated fluorescence. As is shown in Fig. 4 (at +1 h, left panels), 
DNR fluorescence of blast cells exceeded that of lymphocytes, while granulocytes 
14 R • 0.8769 
"'§ 12 p < 0.001 
10 15 20 25 
Mean fluorescence of peripheral blast cells at + 1 h (a.u.) 
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Fig. 3: 
Relationship between DNR 
fluorescence of peripheral blast cells 
and bone marrow blast cells at +I h 
(n = 14 patients on chemotherapy) 
DNR fluorescence was assessed for cells in 
the forward-perpendicular blast window. 
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Fig. 4: 
Cellular DNIR fluorescence in 
subpopulations of hematopoietic 
cells in vivo 
The subpopulations were distinguished 
according to their light scatter properties 
and separately analysed. Upper panels, 
blood at +I h and at + 24 h after start of 
DNR infusion. Lower panels, bone marrow 
at +I hand at +24h. 
ly = lymphocytes; 
bl = blast cells; 
gr = granulocytes. 
Bars indicate median values. 
concentrated relatively more drug than the other cell types. At +24 h (Fig. 4, right 
panels) the same trends in DNR content were observed. In eight patients, in whom 
sufficient numbers of these three subpopulations of cells (i.e., lymphocytes, 
granulocytes and blast cells) were distinguishable in the blood at +1 h, the value of 
the mean DNR fluorescence of granulocytes was set at 100%. The relative mean DNR 
fluorescence of lymphocytic and blast cells were 53% and 88%, respectively 
(Table 2). Thus, the uptake of DNR by leukemic blast cells was intermediate between 
the smaller lymphocytes and the approximately equally large granulocytes. 
Table 2: 
Relative DNR fluorescence in subpopulations of hematopoietic cells in vivo 
Fluorescence 
arbitrary units 
relative% 
Lymphocytes 
7.6±5.63 
53± 16.1 
Blast cells 
11.0± 6.29 
88± 15.2 
Granulocytes 
13.5 ± 8.84 
100 
Cellular DNR fluorescence was measured in three cell types in blood samples of AML 
patients at +I h after start of DNR chemotherapy (n = 8 cases). Cell types were 
distinguished according to their light scatter properties. Fluorescence of the granulocytes 
was set at I 00%. Values are means ± SD. 
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RESPONSE 
Relevance of DNR concentrations in blast cells for the response to treatment 
The relevance of DNR concentrations in blast cells in relation to the outcome of 
treatment was investigated by comparing the DNR concentrations in blast cells 
among the three response categories of patients, i.e., CR, PR or NR patients. The 
amount of DNR present in the bone marrow and the circulating blast cells at +1 h 
showed large interindividual variations (Fig. 5, left panels). At +24 h (Fig. 5, right 
panels) the DNR concentrations in blast cells had decreased to low or undetectable 
levels in most of the patients. Although the CR patients showed a tendency of higher 
DNR levels in blast cells at +1 has compared to PR patients, no statistically 
significant relationship between successful RI and blast cell DNR concentrations 
could be derived from the limited number of data available thus far. It is noteworthy 
that, in analogy with previous reports (38,39), the tumor load parameter (i.e., 
numbers of circulating blast cells at diagnosis) appeared again to correlate with the 
probability to obtain CR, although patient numbers are small. Thus CR patients had 
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Fig. 6: 
Daunorubicin fluorescence of 
peripheral blast cells: negative 
relation with the absolute number of 
peripheral blast cells {CR + PR 
patients, n = I 0 cases) 
Peripheral blast cell values are those at 
diagnosis (i.e., prior to treatment). DNR 
data were obtained at +I hr after IV 
administration of the drug. 
somewhat lower blast cell counts as compared to the PR patients (Table 1), and the 
DNR levels attained in peripheral blast cells at +1 h in CR patients were greater than 
in PR cases. It is not surprising therefore that the peripheral blast cell numbers at 
diagnosis showed an inverse relationship with the DNR concentrations in peripheral 
blast cells at +1 h in CR and PR patients (p < 0.05, Fig. 6). This suggests that the 
uptake of DNR by peripheral blast cells is progressively reduced as a function of 
rising blast cell numbers in the blood. 
The group of NR patients could not be distinguished from the CR patients when DNR 
blast cell levels (Fig. 5) or numbers of peripheral blast cells at diagnosis (Table 1) 
were considered. 
Discussion 
The responsiveness of human AML to cytotoxic drugs is determined by many 
variables. Monitoring of drug levels in AML cells offers another potentially useful 
approach for better understanding the response of individual patients to 
chemotherapy. 
Since the hydroxy metabolite of DNR (DOL) has the same fluorescent properties as 
the parent drug (40,41), flow cytometry detects both compounds and cannot 
discriminate between the parent drug and the metabolite. We used the HPLC 
technique to measure the DOL concentrations of the cell samples. Only minimal 
amounts of cellular DOL were detected by HPLC at +1 hand at +24 h, so that DOL 
contaminated the DNR measurements to a limited extent only. This is in accordance 
with the results from our previous studies dealing with DNR and DOL uptakes by the 
cells (10,34). Those had indicated that the cellular DOL concentrations were 
consistently lower than the cellular DNR concentrations. 
The detection limit of flow cytometry for minimal DNR concentrations is comparable 
to that of HPLC. Although the fluorescent signals obtained from cells incubated in 
vitro with various concentrations of DNR were strong and easily detectable 
(Chapter 3), the fluorescence of cells exposed in vivo to DNR was relatively weak. 
However, HPLC measurements confirmed the relatively low in vivo cellular DNR 
concentrations, so that generally the power of both cellular DNR assays was similar. 
The data of these investigations show that the DNR levels in peripheral blast cells 
and bone marrow blast cells at +1 h correlated well. This is in agreement with the 
concept of exchangeable pools of AML blast cells, traversing between blood and bone 
marrow. In analogy with this, Sahar et al. (27) had reported identical DNR uptakes 
in vitro by leukemic blast cells from peripheral blood and bone marrow, based upon 
flow cytometric analyses. 
It appeared that different types of human hematopoietic cells expressed different 
levels of cellular DNR fluorescence. A progressively greater DNR-associated 
fluorescence was evident for lymphocytes, leukemic blast cells and granulocytes, 
respectively. This trend is suggested, at least in part, to correlate with increased cell 
size. The fact that a part of intracellular DNR is bound to the nucleus (16,42) and 
the rest remains in the cytoplasm, could explain why cells with a large volume (more 
cytoplasm) would generally show a greater DNR fluorescence than those of small 
size. This relationship is not likely to be strict as it appeared that granulocytes, 
being of approximately equivalent size as compared to blasts, concentrated more 
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drug. This is most probably related to the lysosomal granules present in the 
cytoplasm of granulocytes (43) that have been shown to bind DNR (14). 
In a previous study (10) we reported that the probability to obtain a CR was not 
associated with the cellular DNR levels attained in vivo. This study, however, was 
done with total WBC or whole bone marrow nucleated cells. We now examined with 
flow cytometry as to whether the DNR concentrations in the blast cell subset 
selectively could be more predictive for response. It appeared that the CR patients 
could be distinguished from PR patients on the basis of a trend of higher DNR levels 
in blast cells. These observations are of interest in view of the fact that the CR and 
PR patients could also be distinguished by a previously described tumor load 
parameter (38,39) i.e., blast cell counts at diagnosis with high circulating blast cell 
numbers being associated with poor treatment results. Taking these data together an 
inverse relationship became apparent between the numbers of circulating blast cells 
and the DNR levels in peripheral blast cells in the group of CR and PR patients. 
Assuming then that blast cell concentrations of DNR attained in vivo are likely to be 
a function of the tumor load, we propose that lesser amounts of DNR accumulate in 
the blast cells when the circulating blast cell numbers in patients are higher, and 
thus these lower concentrations are less effective in inducing CR. This may represent 
one biological variable of the clinical response to cytotoxic treatment. Accordingly 
we hypothesize that CR patients and PR patients may belong to a similar spectrum of 
varying drug sensitivities, but the fact that PR cases apparently present with a 
higher tumor load may sometimes explain their inferior response to treatment as 
compared to the complete responders. On the other hand, the fact that the NR 
patients could not be distinguished from the CR patients with respect to the DNR 
levels in blast cells or the number of circulating blast cells would be consistent with 
the concept of individual drug sensitivity. In the NR cases an intrinsic factor, i.e., 
intrinsic drug resistance, would most likely be responsible for the poor treatment 
results (44). 
It is also possible that other variables, such as certain non random cytogenetic 
abnormalities, have a strong role in the clinical response of AML patients to 
cytotoxic drugs. The small seize of our series does not lend itself for an adequate 
analysis of clinical, hematological or cytogenetic prognostic variables. The 
cytogenetic findings listed in our study and their relationships with age, sex and CR 
rate have been considered in view of the results of Keating et al.(37). The latter 
investigations have indicated that abnormalities in chromosomes have been noted in 
approximately half of the AML patients. Somewhat more frequent cytogenetic 
abnormalities were found in patients less than 50 years of age and in male patients. 
The resistant disease patients in our series all demonstrated the unfavorable 
karyotypes according to Keating et al. A similar correlation was not apparent for the 
CR and PR patients, but this may be due to the small number of patients in our study. 
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CHAPTER 7 
General discussion 
Introduction 
Knowledge of pharmacokinetics has become important for the effective use of 
several classes of drugs, such as antibiotics, anticonvultants, and cardiovascular 
agents. In the field of cancer chemotherapy, the approach of optimizing treatment in 
clinical situations by using pharmacokinetic information is not generally established. 
This has been due, in part, to the lack of assay methods for detecting low 
concentrations of these extremely chemically reactive compounds which may express 
biological activity at low levels. However, during the last few years the application 
of e.g., high-performance liquid chromatography (HPLC) techniques to the study of 
these drugs has yielded specific and rapid assay methods. Large interindividual 
variations have been found in the absorption, distribution and elimination of many 
antineoplastic agents. So far, in the case of daunorubicin (DNR) treatment of 
patients with acute myeloid leukemia (AML) no attention has been paid to the 
variability of the cellular pharmacokinetics of DNR among subjects and the influence 
of the disease state, which may vary significantly among patients. Therefore, in this 
study an attempt has been made to measure cellular DNR concentrations in AML 
patients during treatment and to interpret the significance of the observed drug 
concentrations in the context of the clinical response to treatment. Thus, the results 
of this study may answer the question whether there is a place for pharmacokinetics 
in the treatment of patients with AML. 
Major conclusions 
Major conclusions from this study were: 
1. Flow cytometry has been shown to be an equally reliable method for measuring 
cellular anthracycline concentrations as HPLC. An advantage of HPLC is the 
possibility to determine the concentrations of the parent drug (DNR) and its main 
metabolite daunorubicinol (DOL) separately. The attractivity of flow cytometry is 
the possibility to relate measurements of anthracycline concentrations to 
subpopulations of hematopoietic cells (i.e., leukemic cells vs normal cells). 
2. The study of cellular pharmacokinetics of DNR in AML patients has shown, that 
the white blood cells (WBC) accumulated the drug. Thereafter, the WBC-plasma 
DNR ratio increased due to the shorter half-time of DNR in plasma than in WBC. 
In addition, the DNR concentrations in WBC and in bone marrow cells correlated 
well at +1 h after DNR injection, although the DNR concentrations in the bone 
marrow cells were consistently lower than the comparative values of DNR in WBC. 
3. With respect to the influence of the pharmacokinetics of DNR on the therapeutic 
effects, the HPLC study revealed that none of the plasma DNR and DOL 
pharmacokinetic parameters (i.e., concentration and area under the curve) 
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predicted for outcome of treatment. In addition, the probability to obtain a 
complete remission (CR) was not associated with the cellular DNR levels attained 
in vivo. 
4. Using flow cytometry, however, it appeared that the CR patients could be 
distinguished from PR patients on the basis of higher DNR levels in leukemic 
blast cells. This suggests that the measurements of DNR concentrations in the 
leukemic blast cell subset could be more predictive for clinical response than 
measurements of total WBC or whole bone marrow cells. 
5. It has already been established that CR and partial response (PR) patients could 
be distinguished by a patient characteristic, i.e., a tumor load parameter (1,2), 
defined by the blast cell counts at diagnosis: high circulating blast cell numbers 
being associated with poor treatment results. AJ3 explanation for high tumor load 
determining an unfavourable treatment result one may consider altered cell 
kinetics or pharmacokinetic differences leading to a deviate pattern of drug 
handling and subsequently less cell kill. The results of our study showed an 
influence of the tumor load on the pharmacokinetics of DNR: an inverse 
relationship became apparent between the numbers of circulating blast cells and 
the DNR levels in these cells in the group of CR and PR patients. Thus, these data 
appear to shed light on the mechanisms of poor response to treatment in patients 
with high tumor load as they attain generally significantly lower cellular drug 
concentrations. These lower concentrations can be regarded as representing one 
of the biological variables responsible for the poor treatment results attained in 
the group of PR patients. On the other hand, the resistant disease (RD) patients 
could not be distinguished from the CR patients with respect to the DNR levels in 
blast cells or the number of circulating blast cells. 
Major discrepancies 
The following issues need further discussion: 
1. The observed relationship between the cellular DNR concentrations in WBC and 
bone marrow cells at +1 h after DNR injection may indicate a rapid penetration of 
free DNR into both cell compartments. Another explanation is the possibility of 
AML blast cells loaded with DNR traversing from blood to bone marrow and 
reversely as has been demonstrated by studying the distribution kinetics of 
untreated leukemia cells in the BNML acute leukemia rat (3). Our study of the 
distribution kinetics of the DNR-carrying BNML cells in the rat (Chapter 4) 
showed that the DNR concentration attained in bone marrow following 
administration of these cells to the rat was of the same order as that after IV 
bolus administration (free DNR) of the same dose. In addition, we could not 
demonstrate any loss of DNR from these cells during circulation. This was evident 
from the lack of detectable plasma DNR concentrations. These data support the 
hypothesis that after IV administration of DNR the drug is taken up by the AML 
blast cells (and other WBC) and transported to the bone marrow. The study of 
cellular pharmacokinetics of DNR in AML patients showed that the cellular DNR 
concentrations in peripheral blast cells and in bone marrow cells correlated well 
but the cellular DNR concentrations in the bone marrow were consistently lower 
than those in peripheral blast cells. 
2. The quantification of plasma concentrations of DNR and its active metabolite 
DOL does not predict their antitumor activity. This situation is contrary to what 
has been observed from traditional drug level monitoring, where blood or plasma 
levels of drugs are representative for their therapeutic efficiency and thus can be 
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used for optimization of the dose and treatment schedules, e.g., in the treatment 
of epilepsy and infectious diseases. However, the cytotoxic effects of DNR, the 
metabolism of DNR, and the mechanisms of resistance to DNR are mainly 
intracellular processes. Differences in drug handling between leukemic blast cells 
may explain the difficulties in using plasma DNR concentrations as a means of 
predicting therapeutic efficiency. 
In contrast to the differences in therapeutic effect of DNR in AML patients, the 
toxic effects of a given dose of DNR to normal tissues show less variability. 
Nausea, vomiting, alopecia and myelosuppression occur in all patients to some 
degree. Theoretically, one might therefore expect a better correlation between 
blood or plasma levels of DNR and toxicity to DNR. The results of our study, 
however, did not disclose a correlation between plasma pharmacokinetics of DNR 
and the duration of the myelosuppression, which was regarded as a parameter of 
toxicity. This lack of correlation suggests more complicated relationships 
between plasma DNR levels and toxicity. For this purpose the routine plasma 
DNR level monitoring in patients with AML does not appear useful. 
3. Although it appeared possible to distinguish CR patients from PR patients on the 
basis of a trend of higher DNR levels in leukemic blast cells, this difference was 
not statistically significant. One reason for this may be the limited number of 
cases on which this study was based. The lack of a strong correlation between 
response and cellular DNR concentrations may reflect the complex relationship 
between tissue drug concentrations and therapeutic effect in vivo. In vitro 
studies, testing the sensitivity of AML cells to DNR, have shown that the survival 
of blast cells following exposure to DNR decreases with increasing cellular drug 
concentrations (6-9), but relatively little is known about the factors that 
influence the relationship between drug concentrations and therapeutic effect in 
man. It must be kept in mind that in determining drug efficacy, the drug (or 
active metabolite) tissue concentrations are only one factor of importance. 
Another i.rllj>Ortant determinant is for instance the sensitivity of a given cell to 
that particular agent. The sensitivity depends on several factors, including cell 
kinetics and intrinsic resistance mechanisms. Thirdly, a complicating factor in 
the interpretation of the complex relationship between tissue drug concentrations 
and therapeutic effect in vivo may be the time that passed between the drug 
concentrations determined during the first 24 hours of the remission induction 
treatment and the therapeutic DNR effect assessed about two to three weeks 
later. It is likely that other approaches will be needed to define the relationship 
between tissue drug concentrations and therapeutic response, including cell 
kinetic phenomena and cell kill studies. 
A fourth factor which must be considered is the common practice of employing 
combinations of antineoplastic agents in AML treatment (i.e., DNR and ara-C). 
This implies that clinical outcome also depends on the efficacy of ara-C which in 
turn will obscure direct relationships between DNR pharmacokinetics and 
treatment results. Simultaneously determined pharmacokinetics of ara-C in AML 
patients during treatment with combination therapy may be helpful in providing 
insight into these effects. 
4. The RD patients could not be distinguished from the CR patients with respect to 
the DNR levels in the blast cells. An explanation is that during a course with 
antineoplastic drugs, a large fraction of the blast cells may be killed, but the 
surviving cells can regrow. The DNR concentration of this subpopulation of 
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biologically important blasts with self-renewal capacity may not be reflected in 
the blast population as a whole and this might explain the lack of a discriminant 
effect in CR versus RD patients. Thus, it may be useful to determine the DNR 
concentrations in subpopulations of leukemic blast cells and to identify the 
occurrence of resistant blast cells, i.e., cells which display the so-called multidrug 
resistant phenotype (10-13). Such cells have to be subject of studies directed to 
the mechanism of resistance to DNR treatment, with the possible result of 
circumvention of DNR resistance in AML patients. 
Future prospects 
If therapy is totally ineffective or so successful that all patients are cured, then the 
analysis of prognostic variables is a waste of time. Considering the current state of 
leukemia treatment, namely that therapy is curative in certain patients but it fails in 
others, the analysis of possible prognostic factors, including the clinical 
pharmacology of DNR, is important. With respect to the question whether in the 
future there may be a place for pharmacokinetics in the treatment of patients with 
AML, the answer is probably yes. However, pharmacokinetic studies should not be 
performed in isolation, but be integrated with other techniques. For instance, a 
valuable interpretation of pharmacokinetics might be done in association with 
studies on intrinsic cell resistance (14-16). In these latter studies a biochemical 
marker (mdr1 mRNA} was compared with in vitro pharmacokinetic studies of DNR, 
in order to demonstrate the presence of MDR in AML cells. It was shown that mdr1 
overexpression in AML cells was associated with a decreased drug accumulation in 
vitro that could be restored by cyclosporin-A. In addition, with the use of a 
clonogenic assay (17) combined with drug uptake studies, it was shown that 
cyclosporin-A not only restored the intracellular DNR accumulation but also the 
DNR sensitivity. These in vitro data indicate that clinical trials with cytotoxic drugs 
in combination with inhibitors of the P-glycoprotein drug pump are warranted. In 
the future therefore, it is likely that DNR pharmacokinetic studies in AML patients 
will support such clinical trials aimed at the treatment of drug resistance in AML 
patients. 
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Summary 
Since its introduction in the late 1960s daunorubicin (DNR), an anthracycline 
antibiotic, has become the major drug effective in the treatment of acute myeloid 
leukemia (AML). Combination therapy with cytarabine (ara-C) is commonly used for 
induction of complete remission (CR) in AML, with CR rates up to 60-80%. Despite 
the advances in the treatment of AML, CR rates and their duration vary significantly 
among patients. Certain patients may be cured, others do not respond to therapy and 
have an extremely grave prognosis. These differences may be related at least in part 
to differences in metabolism and distribution of the drug. The investigations 
described in this thesis deal with the identification of pharmacokinetic variables of 
DNR that may give insight into the mechanisms which are responsible for individual 
differences of clinical response of AML patients to therapy. 
In chapter 1 a short overview is given of the pharmacology of DNR and of what is 
known about DNR plasma pharmacokinetic parameters in relation to response. This 
discussion results in the suggestion that instead of plasma DNR levels, measurements 
of cellular DNR concentrations may be more useful for clinical correlations. 
In chapter 2 the evaluation of certain factors which directly affect the quantification 
of cellular DNR using high-performance liquid chromatography (HPLC) is described. 
It appeared, that the best recovery of leukocytes from the blood is attained when 
cold hypotonic lysis is used. It could be performed at 0-4 ·c, with excellent 
separation of white and red blood cells and 100% recovery of all nucleated cells. The 
best extraction recoveries of DNR, daunorubicinol (DOL), and doxorubicin from 
human leukocytes is attained with high-volume extraction (5 ml extraction mixture). 
However, the recoveries remained dependent on the cellularity of the cell sample. To 
account for these cellularity-related recoveries a correction factor was needed to 
calculate the DNR and DOL contents of the leukocytes. In addition, the WBC and 
bone marrow samples of AML patients were standardized with PBS at final 
concentrations between 109 to 10 x 109 cells/1 before entering the extraction 
procedure. The obtained data were applied to measure plasma and cellular DNR and 
DOL levels in seven patients with AML during their first course of remission 
induaction (RI) therapy. The cellular DNR levels varied over a broad range and did 
not correlate with plasma pharmacokinetics. 
In chapter 3 the applicability of flow cytometry for measuring cellular DNR 
concentrations was validated with the use of a conventional HPLC method. It 
appeared, that the DNR related fluorescence signals obtained from cells and nuclei 
measured with flow cytometry correlated well with the absolute amount of DNR 
(assessed with HPLC) in the cells as well as the nuclei. In addition, it was shown that 
the nuclear DNR associated fluorescence involves DNR bound to the nucleus rather 
than free DNR. These data support the conclusion that flow cytometric 
measurements of cellular DNR represent the total (i.e., cytoplasm and nuclear bound) 
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DNR content of cells. Flow cytometry was subsequently applied in the study of the in 
vivo cellular pharmacokinetics of DNR in AML, described in chapter 6. 
In chapter 4 the capability of nucleated bone marrow cells and leukemic cells 
(Brown Norway acute myeloid leukemia, BNML) to transport DNR to target tissues in 
the body was investigated in the rat. The cells in vitro took up DNR according to a 
linear pattern. When these DNR loaded cells were infused in the rat, dose dependent 
distribution kinetics were observed. Compared to IV injection of the same dosage, 
cell-bound DNR leads to higher DNR concentrations in the liver and in the spleen, 
while equal DNR levels were attained in bone marrow. Lower DNR concentrations 
were observed in cardiac tissue. Hence, DNR entrapped into bone marrow and 
leukemia cells follows different kinetics than does free DNR in plasma. 
In chapter 5 the study of plasma and cellular pharmacokinetics of DNR measured 
with HPLC was applied to and evaluated in 37 AML patients during their first RI 
treatment with DNR and ara-C. Plasma DNR concentrations did not correlate with 
DNR concentrations in bone marrow nucleated cells. However, plasma area under 
the curve (AUC) values of DNR correlated inversely with AUC values of DNR in white 
blood cells (WBC). In addition, concentrations of DNR in WBC correlated positively 
with DNR concentrations in bone marrow nucleated cells. None of the plasma levels 
or WBC and bone marrow concentrations had predictive value for clinical response 
to therapy. Notably, the concentrations of DNR in WBC showed a negative 
correlation with the numbers of peripheral blast cells at diagnosis, suggesting that 
the effective DNR concentrations achieved intracellularly are mainly a function of 
the tumor load. This suggests that lesser amounts of DNR accumulate intracellularly 
when AML cell numbers in blood are higher. 
In chapter 6 cellular DNR concentrations of leukemic cells in blood and bone 
marrow were measured with flow cytometry. The data were obtained in 17 AML 
patients during their first RI treatment with DNR and ara-C. The results indicate 
that DNR fluorescence of leukemic blast cells is intermediate between the smaller 
lymphocytes and the approximately equally large granulocytes. It was also shown, 
that the DNR fluorescence of peripheral blast cells and bone marrow blast cells 
correlated well. With respect to the response to treatment, it appeared that the CR 
patients could be distinguished from partial response (PR)~atients on the basis of a 
trend of higher DNR levels in blast cells. The CR and PR patients could also be 
distinguished by the number of circulating blast cells and an inverse relationship 
became apparent between the numbers of circulating blast cells and the DNR levels 
in these cells. On the other hand, resistant disease patients could not be 
distinguished from the CR patients on the basis of DNR pharmacokinetics or tumor 
load parameters, suggesting that most likely intrinsic drug resistance is responsible 
for the poor treatment results in these cases. 
Finally, in chapter 7 the results of this thesis are discussed against the background 
of the question whether there is a place for pharmacokinetics in the treatment of 
patients with AML. 
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Samenvatting 
Sinds eind jaren zestig neemt daunorubicine (DNR), een cytostaticum uit de 
anthracycline antibioticum groep, een belangrijke plaats in bij de behandeling van 
patienten met acute myeloide leukemie (AML). Bij het induceren van een complete 
remissie wordt meestal gebruik gemaakt van een combinatietherapie bestaande uit 
DNR en cytarabine (ara-C) waarmee remissie percentages van 60% tot 80% bereikt 
kunnen worden. Ondanks de geboekte vooruitgang in de behandeling van patienten 
met AML, zijn er tach nog grate verschillen in response waar te nemen tussen de 
patienten onder ling. Deze verschillen betreffen zowel het aldan niet bereiken van 
een complete remissie als ook de variabele duur van een eventueel bereikte remissie. 
Dit betekent dat de behandeling voor bepaalde patienten leidt tot genezing van hun 
leukemie, maar dit betekent ook dat er patienten zijn die niet goed op de therapie 
reageren en waarbij de leukemie cellen niet uit het lichaam verdwijnen. Voor deze 
laatste groep van patienten is de kans op genezing gering en de prognose erg somber. 
Het is mogelijk dat de verschillen in individuele response gedeeltelijk terug te voeren 
zijn op verschillen in metabolisme en verdeling van DNR in het lichaam. In dit 
proefschrift is een aanzet gegeven tot het bestuderen en identificeren van 
farmacokinetische varia belen van DNR in patienten met AML, met als doel het 
vergroten van ons inzicht in de factoren die bepalend zijn voor de therapie resultaten. 
In hoofdstuk 1 wordt een overzicht gegeven van de farmacologie van DNR en van de 
plasma farmacokinetische parameters van DNR in relatie tot de response in 
patienten met AML. De resultaten van de beschreven studies hebben geleid tot de 
vraag of het bepalen van cellulaire DNR concentraties, in plaats van plasma DNR 
concentraties, niet zinvoller is bij het bestuderen van de relatie tussen 
farmacokinetiek en response. 
In hoofdstuk 2 wordt de hoge druk vloeistof chromatografie (HPLC) methode 
beschreven die in dit onderzoek gebruikt is om de concentraties van DNR in plasma 
en in de cellen te meten. Met name bij het kwantificeren van de hoeveelheid cellulair 
DNR zijn een aantal factoren van belang gebleken. Zo bleek dat met behulp van 
koude (0-4 "C) hypotone lysis een maximaal rendement van de isolatie van 
leukocyten uit bloed te verkrijgen was: de rode en de witte bloedcellen werden goed 
van elkaar gescheiden waarbij 100% van de kernhoudende cellen werd 
teruggevonden. Met betrekking tot de extractie van DNR, daunorubicinol (DOL) en 
doxorubicine uit menselijke leukocyten gaf de methode van groat-volume extractie 
(5 ml extractie mengsel) de beste resultaten. Ondanks het gebruik van een groat 
extractie volume, bleef het rendement van de extractie van DNR en DOL uit cellen 
afhankelijk van het aantal cellen aanwezig in het te bepalen monster. Het was 
daarom noodzakelijk om bij het berekenen van de cellulaire concentraties van DNR 
en DOL gebruik te maken van een correctie factor. Tevens werd het celaantal van de 
te extraheren bloed en beenmerg monsters gestandaardiseerd door de monsters te 
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verdunnen met PBS tot eindconcentraties van 1 tot 10 x 109 cellen per liter. Met 
behulp van de beschreven HPLC methode werden DNR en DOL concentraties gemeten 
in plasma en cellen afkomstig van zeven patienten met AML tijdens hun eerste 
remissie inductie kuur. De gemeten cellulaire DNR concentraties lieten grate 
verschillen zien tussen de patienten onderling. Er waren geen relaties waarneembaar 
tussen de plasma DNR concentraties en de cellulaire DNR concentraties. 
In hoofdstuk 3 wordt de toepasbaarheid van de laser flow cytometriemethode 
beschreven bij het bepalen van de cellulaire DNR concentraties, waarbij de 
resultaten vergeleken worden met de eerder beschreven HPLC methode. Het bleek 
dat de fluorescentie signalen afkomstig van DNR in cellen en kernen (gemeten met de 
flow cytometer) goed overeen kwamen met de absolute hoeveelheid DNR in de cellen 
en kernen (gemeten met HPLC). Dialyse experimenten toonden aan dat de kern 
fluorescentie van DNR voor het grootste deel afkomstig is van DNR gebonden in de 
kern en in mindere mate afkomstig is van vrij in de kern aanwezig DNR. Deze 
resultaten ondersteunen de conclusie dat met behulp van flow cytometrie de totale 
cellulaire DNR concentratie (DNR in cytoplasma en DNR gebonden in de kern) 
aangetoond wordt. De flow cytometrie methode is aansluitend gebruikt voor het 
bepalen van de cellulaire DNR concentraties in AML patienten (beschreven in 
hoofdstuk 6). 
In hoofdstuk 4 wordt het mogelijke aandeel in het transport van DNR naar de 
weefsels door normale en leukemische kernhoudende cellen beschreven. Het opladen 
van de cellen met DNR in vitro verliep volgens een lineair patroon. Na het inspuiten 
van deze cellen in de bloedbaan van de rat werden dosis afhankelijke DNR 
concentraties in de weefsels gemeten. De DNR weefsel concentraties na toediening 
van met DNR opgeladen cellen werden vergeleken met DNR weefsel concentraties 
verkregen na toediening van eenzelfde hoeveelheid DNR intraveneus. Verschillen in 
DNR weefselverdeling werden gevonden: na toediening van celgebonden DNR waren 
de DNR concentraties in lever en milt hager en in hartweefsellager dan na 
intraveneus toegediend DNR. Opvallend was de bevinding dat de DNR concentraties 
in beenmerg vergelijkbaar waren. 
In hoofdstuk 5 wordt beschreven hoe de HPLC methode gebruikt werd voor het 
meten van DNR concentraties in plasma en in cellen (bloed en beenmerg) afkomstig 
van 37 patienten met AML tijdens hun eerste kuur met DNR en ara-C. De plasma 
DNR concentraties correleerden niet met de DNR concentraties gemeten in de 
kernhoudende cellen van het beenmerg. Er bleek wel een verband te bestaan tussen 
de DNR concentraties in plasma en in de witte bloedcellen: de oppervlakte onder de 
concentratie-tijd-curve (AUC) van DNR in plasma was negatief gecorreleerd met de 
AUC van DNR in de witte bloedcellen. Tevens correleerden de DNR concentraties in 
witte bloedcellen met de DNR concentraties van de kernhoudende cellen van het 
beenmerg. De gemeten DNR concentraties in plasma, witte bloedcellen of 
beenmergcellen hadden geen voorspellende waarde met betrekking tot de klinische 
respone op de ingestelde behandeling met DNR. 
Opvallend was de relatie tussen de DNR concentraties in de witte bloedcellen en het 
aantal blasten die in het bloed aanwezig waren op het moment dat de diagnose AML 
werd gesteld. Naarmate er meer blasten in het bloed aanwezig waren werden er 
lagere cellulaire DNR concentraties gemeten. Hieruit blijkt dat de te bereiken 
cellulaire DNR concentratie mogelijk afhankelijk is van het aantal aanwezige 
tumorcellen. 
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In hoofdstuk 6 wordt beschreven hoe de DNR concentraties in blasten, afkomstig uit 
bloed en beenmerg van 17 paW~nten met AML, gemeten werden met behulp van de 
flow cytometer. De hoeveelheid DNR in blasten was boger dan de DNR concentraties 
gemeten in de kleinere lymfocyten, maar lager dan de DNR concentraties in de qua 
grootte vergelijkbare granulocyten. De DNR concentraties in blasten uit het bloed 
correleerden positief met de DNR concentraties in beenmerg blasten. De DNR 
concentraties in blasten werden ook vergeleken met de klinische response op de 
behandeling met DNR. Het bleek dat de patienten die in complete remissie kwamen 
werden gekenmerkt door hogere DNR concentraties dan de patienten die slechts een 
partiele response op de therapie vertoonden. Deze twee groepen van patienten 
konden ook van elkaar onderscheiden worden op grond van het aantal blasten in het 
bloed. Tevens bleek dat de hoeveelheid DNR in de blasten negatief gecorreleerd was 
met het aantal blasten in het bloed. Opvallend was de bevinding dat de patienten die 
niet goed op de therapie hadden gereageerd (refractaire leukemie patienten) op basis 
van de gemeten DNR concentraties in blasten en op basis van het aantal blasten in 
het bloed niet konden worden onderscheiden van de complete remissie patienten. Bij 
de refractaire patienten zijn waarschijnlijk andere factoren, zoals het multidrug 
resistentie fenotype, verantwoordelijk voor de slechte therapie resultaten. 
Tenslotte worden in hoofdstuk 7 de resultaten van dit onderzoek besproken in het 
kader van de vraag of het toepassen van farmacokinetische studies van DNR, nu en 
in de toekomst, van belang is bij de behandeling van AML patienten met DNR. 
93 
Dankwoord 
Graag wil ik iedereen bedanken die een bijdrage heeft geleverd aan de 
totstandkoming van dit proefschrift, met name: 
Prof. dr. Bob Lowenberg, mijn promotor, voor zijn constante enthousiasme bij de 
begeleiding van het onderzoek en vooral voor zijn stimulans om de resultaten zoveel 
mogelijk te publiceren en op wetenschappelijke bijeenkomsten te presenteren. 
Dr. Pieter Sonneveld voor zijn grate inzet bij de start en de uitvoering van het 
onderzoek en voor de pittige discussies. 
Prof. dr. D.W. van Bekkum, Prof. dr. G.H. Blijham en Prof. dr. R. Willemze voor de 
beoordeling van het manuscript. 
Koos van der Steuijt voor zijn grate bijdrage aan het uitvoeren van de vele 
experimenten en voor zijn kritische houding tijdens het werken. 
Dr. Kees Nooter (T.N.O., Rijswijk) voor de waardevolle samenwerking en voor de 
genoten gastvrijheid op zijn laboratorium. 
Dr. Ruud Delwel voor zijn aandeel in de FACS metingen. 
Ir. Frank Schultz (T.N.O., Rijswijk) voor zijn hulp bij het rekenwerk met de 
computer. 
Drs. Marijke Bontenbal, collega-onderzoeker en vriendin door dik en dun, voor haar 
onmisbare steun. 
Dr. Ton Hagenbeek en drs. Willemijn Sizoo voor hun betrokkenheid bij het 
onderzoek. 
De verpleegkundigen van de afdeling hematologie van de Dr. Daniel den Hoed 
Kliniek voor hun hulp bij het afnemen van de materialen bij de patiE~nten. 
Mevr. E. Vonk-Neele, mevr. M. Westerhout-Kersten en mevr. M. van der Kroon voor 
het opzoeken van de literatuur referenties. 
Mevr. A. Sugiarsi, Inge Dijkstra, Thea van Vlijmen, Yvonne Lauer en Jeanne 
Vlasveld voor alle secretariaatswerkzaamheden. 
Hans Vuik, Sten Sliwa, Johan Marselje en Jacqueline de Ruyter voor het 
vervaardigen van de figuren. 
Alle mederwerkers van het Celkweeklaboratorium en van de afdeling Biochemie 
voor de prettige contacten en samenwerking. 
Joop Kokenberg, mijn broer, voor de vormgeving van het proefschrift. 
Mijn ouders die mij een academische opleiding hebben laten volgen en mijn familie 
en vrienden voor hun morele steun. 
Tenslotte Hans, mijn echtgenoot, voor zijn steun en hulp tijdens de afgelopen drukke 
en soms ongemakkelijke periode. Ik hoop dat we binnenkort weer meer tijd hebben 
om samen door te kunnen brengen. 
94 
Curriculum vitae 
De schrijfster van dit proefschrift werd geboren op 27 december 1958 te 
's-Gravenhage. 
Na het behalen van het diploma Atheneum Bin 1977 aan het Thomas More College 
te 's-Gravenhage werd in datzelfde jaar begonnen met de studie geneeskunde aan de 
Erasmus Universiteit te Rotterdam. In maart 1984 werd deze studie voltooid met het 
artsexamen. 
Van maart 1984 tot januari 1988 was zij verbonden aan de afdeling Klinische 
Farmacologie van de Dr. Daniel den Hoed Kliniek/Rotterdamsch Radio-
Therapeutisch Instituut. In deze periode werkte zij, onder supervisie van 
Dr. B. Lowenberg en Dr. P. Sonneveld, aan klinisch farmacologisch onderzoek van 
cytostatica bij leukemie patienten. Het onderzoek, financieel mogelijk gemaakt door 
het Koningin Wilhelmina Fonds, heeft geresulteerd in dit proefschrift. 
Vanaf januari 1988 is zij in opleiding tot Medisch Microbioloog op de afdeling 
Klinische Microbiologie en Ziekenhuishygiene (Hoofd: Prof. dr. D.M. MacLaren) van 
het Academisch Ziekenhuis der Vrije Universiteit te Amsterdam. 
95 

